Downloads: 1
[55d924]:
/
SearchResults.csv
| # | Rank | NCT Number | Title | Acronym | Status | Study Results | Conditions | Interventions | Outcome Measures | Sponsor/Collaborators | Gender | Age | Phases | Enrollment | Funded Bys | Study Type | Study Designs | Other IDs | Start Date | Primary Completion Date | Completion Date | First Posted | Results First Posted | Last Update Posted | Locations | Study Documents | URL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | NCT04068974 | Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer | Recruiting | No Results Available | Recurrent Platinum-resistant Ovarian Cancer | Drug: Camrelizumab (SHR-1210)|Drug: Apatinib | Objective Response Rate|Progression Free Survival|Disease Control Rate|Duration of Response (DoR)|Assessment of safety | Peking Union Medical College Hospital | Female | 18 Years to 70 Years (Adult, Older Adult) | Phase 2 | 28 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | OBU-OvaC-IIT-SHR1210-APA | October 28, 2019 | June 30, 2021 | June 30, 2022 | August 28, 2019 | March 16, 2021 | Peking Union Medical College Hospital, Beijing, China | https://ClinicalTrials.gov/show/NCT04068974 | |||
| 2 | 2 | NCT03398655 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) | OVAL | Recruiting | No Results Available | Recurrent Platinum Resistant Ovarian Cancer | Drug: VB-111 + Paclitaxel|Drug: Placebo + Paclitaxel | Overall Survival|Progression Free Survival (PFS) by RECIST 1.1|Combined CA-125 and RECIST 1.1 response (GCIG)|CA-125 Response (GCIG)|Objective response rate (ORR) by RECIST 1.1|OS100 for a sensitivity analysis of OS | Vascular Biogenics Ltd. operating as VBL Therapeutics|GOG Foundation | Female | 18 Years and older (Adult, Older Adult) | Phase 3 | 400 | Industry|Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | VB-111-701/GOG-3018 | December 19, 2017 | December 2022 | June 2023 | January 12, 2018 | November 26, 2021 | UAB Division of GYN Oncology, Birmingham, Alabama, United States|Western Regional Medical Center, Goodyear, Arizona, United States|Arizona Oncology Associates, PC - HAL - USO, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HAL - USO, Tempe, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|UCLA-JCCC-Women's Health Clinical Research Unit, Los Angeles, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|University of California, Irvine Medical Center/Chao Family Comprehensive Cancer Center, Orange, California, United States|University of California - San Francisco, San Francisco, California, United States|Sansum Clinic - USO, Santa Barbara, California, United States|Olive View UCLA Medical Center, Sylmar, California, United States|Hartford HealthCare Cancer Institute at the Hospital of Central Ct, Hartford, Connecticut, United States|Hartford Healthcare, Hartford, Connecticut, United States|UF Health, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Midwestern Regional Medical Center, Inc, Zion, Illinois, United States|Parkview Cancer Institute, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Health Hospital, Detroit, Michigan, United States|Dartmouth- Hitchcock Medical Center, Lebanon, New Hampshire, United States|Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Women's Cancer Care Associates, LLC, Albany, New York, United States|Westchester Medical Center, Hawthorne, New York, United States|Northwell Health Cancer Institute, Lake Success, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Health Quest Medical Practice, Division of Gynecology/Oncology Gyno Dyson Cancer Center Vassar Brothers Medical Center, Poughkeepsie, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|UNC Chapel Hill, Chapel Hill, North Carolina, United States|Duke University-Duke Cancer Institute, Durham, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Sanford Medical Center, Fargo, North Dakota, United States|University of Cincinnati, Cincinnati, Ohio, United States|Womens Cancer Center/Kettering Cancer Care, Kettering, Ohio, United States|University of Oklahoma Health Sciences Center-Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|GHS Cancer Institute, Greenville, South Carolina, United States|Sanford Clinical Research, Sioux Falls, South Dakota, United States|Texas Oncology, Austin Central - USO, Austin, Texas, United States|Memorial Hermann, Houston, Texas, United States|UT Health, San Antonio, Texas, United States|Universtiy of Vermont, Burlington, Vermont, United States|MultiCare Institute for Research & Innovation, Tacoma, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|Marshfield Clinic Cancer Care & Research Center, Marshfield, Wisconsin, United States|Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Shaare Tzedek Medical Center, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Department of Oncology, Rehovot, Israel|Aichi Cancer Center, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Ehime University Hospital, Tōon, Ehime, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Iwate Medical University Hospital, Shiwa-gun, Iwate, Japan|Tohoku University Hospital, Sendai, Myagi, Japan|National Defense Medical College Hospital, Tokorozawa, Saitama, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto, Tokyo, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Hokkaido University Hospital, Sapporo, Japan|Centrum Badan Klinicznych Jagiellonskiego Centrum Innowacji, Kraków, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn, Poland|MedPolonia Sp. z o.o., Poznań, Poland|Parc Taulí Hospital Universitari Edifici Santa Fe, Planta 0, Sala de recerca 3, Barcelona, Spain|Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitario de Donostia Edificio Onkologikoa- Planta baja, Sala de Ensayos Clinicos, Donostia, Spain|Hospital Gregorio Marañon Módulo prefabricado Oncología, Planta Baja, Madrid, Spain|MD Anderson Cancer Center Madrid Unidad de ensayos Clinicos, Madrid, Spain|Hospital Universitario Clínico San Carlos., Madrid, Spain|Hospital Universitario Virgen del Rocío Servicio Oncología Médica. Ensayos Clínicos. Edificio CDCA, Sevilla, Spain|Instituto Valenciano de Oncología Médica (IVO, Valencia, Spain|Consorcio Hospitalario General Universitario de Valencia Servicio de Oncología Médica - Unidad de Investigación, Valencia, Spain | https://ClinicalTrials.gov/show/NCT03398655 | ||
| 3 | 3 | NCT05145218 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer | Recruiting | No Results Available | Recurrent Platinum-resistant Ovarian Cancer | Drug: Anlotinib Hydrochloride Capsules|Drug: Paclitaxel injection|Drug: TQB2450 injection | Disease progression-free survival(PFS) evaluated by Independent Review Committee(IRC)|Overall survival (OS)|Disease PFS evaluated by investigators|PFS rate of 6 months: including PFS rate of 6 months evaluated by IRC and investigators;|Objective response rate (ORR) evaluated by IRC and investigators|Duration of response (DOR)|Disease Control Rate (DCR)|OS rate of 12 months|Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)，as well as abnormal laboratory examination indicators. | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Female | 18 Years to 75 Years (Adult, Older Adult) | Phase 3 | 405 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | TQB2450-III-10 | September 28, 2021 | October 2024 | December 2024 | December 6, 2021 | December 8, 2021 | Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|AnYang Tumor Hospital, AnYang, Henan, China | https://ClinicalTrials.gov/show/NCT05145218 | |||
| 4 | 4 | NCT01653912 | Dose-finding Study in Platinum-Resistant Ovarian Cancer | Completed | Has Results | Recurrent Platinum-resistant Ovarian Cancer | Drug: GSK2110183 in combination with carboplatin and paclitaxel | Phase 1: Number of Subjects With Treatment-Emergent Adverse Events (TEAE) of Grade Greater Than or Equal to (≥) 3 in Severity|Phase 1 Safety: Number of Subjects Reporting Adverse Events|Phase 1: Maximum Tolerated Dose (MTD) of GSK2110183|Overall Response Rate (ORR) in Phase 2 Subjects With Recurrent Platinum-resistant Ovarian Cancer (Cohort A)|ORR in Phase 2 Subjects With Recurrent Platinum-refractory Ovarian Cancer (Cohort B)|ORR in Phase 1 Subjects With Recurrent Platinum-resistant Ovarian Cancer|Phase 2: Number of Subjects With Treatment-Emergent Adverse Events (TEAE) of Grade ≥3 in Severity|Phase 2 Safety: Number of Subjects Reporting Adverse Events|Phase 2: Response Rate (RR) Defined by Gynecologic Cancer Intergroup (GCIG) CA 125|Progression Free Survival (PFS) by RECIST or Clinical Symptomatic Progression of Subjects With Recurrent Platinum-resistant Ovarian Cancer (Phase 2-Cohort A)|PFS by RECIST of Subjects With Recurrent Platinum-resistant Ovarian Cancer (Phase 2-Cohort A) | Accenture | Female | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 59 | Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | PKB116611|2012-002483-27 | November 2012 | July 2015 | November 2015 | July 31, 2012 | April 2, 2018 | April 2, 2018 | Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|Western Hospital, Footscray, Victoria, Australia|Royal Women's Hospital, Parkville, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Medical Radiology Scientific Center of Ministry of Healthcare and Social Development of RF, Omskaya, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|Mount Vernon Cancer Center, Northwood, Middlesex, London, United Kingdom|Royal Surrey County Hospital NHS Foundation Trust, Guildford, Surry, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom | https://ClinicalTrials.gov/show/NCT01653912 | ||
| 5 | 5 | NCT03467178 | Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. | MITO29 | Recruiting | No Results Available | Recurrent, Platinum-resistant Ovarian Cancer | Drug: Decitabine|Drug: Carboplatin|Drug: Pegylated Liposomal Doxorubicin|Drug: Gemcitabine|Drug: Paclitaxel | Progression free survival (PFS)|Overall survival (OS)|Radiological response rate (in patients with measurable disease)|Duration of response|Cancer-Antigen 125 (CA-125) response rate per GCIG (Gynaecologic Cancer Intergroup) and change in CA-125|Toxicity profile|Patient Reported Outcome: Physical well-being|Patient Reported Outcome: Social/family well-being|Patient Reported Outcome: Functional well being|Patient Reported Outcome: Emotional well being | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 119 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | INT 189-17 | July 30, 2018 | December 2021 | December 2021 | March 15, 2018 | September 5, 2021 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy | https://ClinicalTrials.gov/show/NCT03467178 | ||
| 6 | 6 | NCT03949283 | Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | Recruiting | No Results Available | Recurrent Ovarian Carcinoma|Platinum-resistant Ovarian Cancer | Diagnostic Test: ChemoID Assay|Drug: Standard Chemotherapy | Objective response rate|Progression Free Survival (PFS)|Duration of Response|CA125 levels|Health-Related Quality of Life (HRQOL) | Cordgenics, LLC | Female | 18 Years and older (Adult, Older Adult) | Phase 3 | 220 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | CG03 | July 26, 2019 | June 30, 2024 | December 30, 2024 | May 14, 2019 | October 25, 2021 | Arizona Oncology, Phoenix, Arizona, United States|Kaiser Permanente, Los Angeles, California, United States|Miami Cancer Institute/Baptist Health South Florida, Miami, Florida, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|LSU Health Sciences Center, New Orleans, Louisiana, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|West Penn Hospital, Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Charleston Area Medical Center (CAMC), Charleston, West Virginia, United States|Edwards Comprehensive Cancer Center - Cabell Huntington Hospital, Huntington, West Virginia, United States | https://ClinicalTrials.gov/show/NCT03949283 | |||
| 7 | 7 | NCT04374630 | Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian | PROFECTA-II | Recruiting | No Results Available | Platinum-resistant Ovarian Cancer | Drug: Paclitaxel|Drug: Afuresertib | PFS based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|Overall survival (OS)|Objective response rate (ORR) according to RECIST 1.1|Duration of response (DOR) according to RECIST 1.1|Disease control rate (DCR) according to RECIST 1.1|Best overall response (BOR) according to RECIST 1.1|Cancer antigen 125 (CA-125) response (Gynecological Cancer Intergroup [GCIG])|Pharmacokinetics (PK) of afuresertib and paclitaxel in patients with PROC under combination therapy of afuresertib plus paclitaxel, or paclitaxel alone at steady-state To explore potential effect of coadministration of afuresertib|Rate and severity of treatment-emergent adverse events (TEAEs) based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0|Vital signs|Electrocardiogram (ECG)|Physical examinations|CBC|Clinical Chemistry | Laekna Limited | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 141 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | LAE002INT2001 | June 9, 2020 | July 25, 2022 | January 25, 2023 | May 5, 2020 | December 2, 2021 | Arizona Oncology Associates, Phoenix, Arizona, United States|Arizona Oncology, Tucson, Arizona, United States|Highlands Oncology Group, Rogers, Arkansas, United States|Gynecology Oncology Associates Newport Beach, Newport Beach, California, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|University of Chicago, Chicago, Illinois, United States|Women's Cancer Care, Covington, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Southwest Women's Oncology Group, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|OHCare Oncology Hematology Care (OHC), Inc. - Kenwood Office, Cincinnati, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Abington Memorial Hospital, Willow Grove, Pennsylvania, United States|Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|USO Texas Oncology, Longview, Texas, United States|US Texas Oncology, San Antonio, Texas, United States|Baylor Scott & White Medical Center, Temple, Texas, United States|Texas Oncology, The Woodlands, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States | https://ClinicalTrials.gov/show/NCT04374630 | ||
| 8 | 8 | NCT02889900 | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer | CONCERTO | Completed | Has Results | Recurrent Platinum Resistant Ovarian Cancer | Drug: cediranib and olaparib | Mean Objective Response Rate (ORR) by Independent Central Review (ICR) Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)|ORR by Investigator Assessment Using RECIST 1.1|Median Duration of Response (DoR) by ICR and Investigator Assessment Using RECIST 1.1|Disease Control Rate (DCR) by ICR and Investigator Assessment Using RECIST 1.1|Median PFS by ICR and Investigator Assessment Using RECIST 1.1|Median Time to Treatment Discontinuation or Death (TDT)|Median Overall Survival (OS)|Best Observed Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30 Scales|Best Observed Change From Baseline in EORTC QLQ-OV28 | AstraZeneca|Myriad Genetic Laboratories, Inc.|Merck Sharp & Dohme Corp. | Female | 18 Years to 120 Years (Adult, Older Adult) | Phase 2 | 62 | Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | D8488C00001 | January 17, 2017 | August 27, 2019 | March 16, 2021 | September 7, 2016 | August 20, 2020 | June 11, 2021 | Research Site, Mobile, Alabama, United States|Research Site, Anchorage, Alaska, United States|Research Site, Downey, California, United States|Research Site, Greenbrae, California, United States|Research Site, Los Angeles, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Newnan, Georgia, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Westwood, Kansas, United States|Research Site, Covington, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Billings, Montana, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Seattle, Washington, United States | "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02889900/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02889900/SAP_001.pdf | https://ClinicalTrials.gov/show/NCT02889900 |
| 9 | 9 | NCT02641639 | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | Terminated | No Results Available | Platinum Resistant Ovarian Cancer | Drug: Fosbretabulin tromethamine|Drug: Placebo | Progression free survival|Improvement in objective response rate|Evaluation of overall survival (OS)|Proportion of subjects who remain progression-free at 6, 9, and 12 months|Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo | Mateon Therapeutics | Female | 18 Years and older (Adult, Older Adult) | Phase 2|Phase 3 | 91 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | OX4325 | June 2016 | October 2017 | October 2017 | December 29, 2015 | March 22, 2018 | University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Mitchell Cancer Institute - USA Health System, Mobile, Alabama, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|Oncology Institute of Hope and Innovation, Lynwood, California, United States|University of California Irvine, Orange, California, United States|California Pacific Medical Center, Research Institute, San Francisco, California, United States|Sansum Clinic, Santa Barbara, California, United States|Rocky Mountain Cancer Centers, LLP, Lakewood, Colorado, United States|Hartford Health Care Cancer Institute; Affiliate Memorial Sloan Kettering, Hartford, Connecticut, United States|Stamford Hospital - Bennett Cancer Center, Stamford, Connecticut, United States|Sylvester Comprehensive Cancer Center University of Miami, Miami, Florida, United States|Baptist Health Medical Group Oncology, LLC, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Augusta University, Augusta, Georgia, United States|Maine Medical Center, Scarborough, Maine, United States|Mercy Medical Center; The Institute for Cancer Care, Baltimore, Maryland, United States|HCA Midwest Division - Sarah Cannon Cancer Institute, Kansas City, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Oklahoma Heath Sciences Center - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|OHSU Center for Women's Health & Knight Cancer Institute, Portland, Oregon, United States|Willamette Valley Cancer Institute, Springfield, Oregon, United States|Lehigh Valley Hospital, John and Dorothy Morgan Cancer Center; Affiliate Memorial Sloan Kettering, Allentown, Pennsylvania, United States|The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Gibbs Cancer Center & Research Institute Spartanburg Medical Center, Spartanburg, South Carolina, United States|Texas Oncology, P.A., Austin, Texas, United States|Texas Oncology, Bedford, Texas, United States|Dallas County Hospital District d/b/a Parkland Health and Hospital System, Dallas, Texas, United States|Simmons Comprehensive Cancer Center; UT Southwestern Medical Center, Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology San Antonio, San Antonio, Texas, United States|Texas Oncology, P.A., The Woodlands, Texas, United States|Texas Oncology, P.A., Tyler, Texas, United States|UZ Leuven, Leuven, Belgium|Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum Essen (AöR) Klinik für Frauenheilkunde und Geburtshilfe, Essen, Germany|Universitäts-Frauenklinik Dept. für Frauengesundheit, Tubingen, Germany | https://ClinicalTrials.gov/show/NCT02641639 | |||
| 10 | 10 | NCT05198804 | A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | Not yet recruiting | No Results Available | Ovarian Cancer|Platinum-resistant Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer | Drug: ZN-c3|Drug: Niraparib | Phase 1: Incidence and severity of Dose Limiting Toxicities (DLTs) in DLT-evaluable subjects during Cycle 1|Phase 2: To investigate the antitumor activity of ZN-c3 in combination with niraparib - Progression Free Survival at 4 months|Phase 2: To investigate the antitumor activity of ZN-c3 in combination with niraparib - Objective Response Rate|To further investigate the antitumor activity of ZN-c3 in combination with niraparib - Duration of response|To further investigate the antitumor activity of ZN-c3 in combination with niraparib - Clinical Benefit Rate|To further investigate the antitumor activity of ZN-c3 in combination with niraparib - Objective Response Rate|To investigate the OS of subjects receiving ZN-c3 in combination with niraparib|To investigate the safety and tolerability of ZN-c3 in combination with niraparib|To evaluate changes in Patient Reported Outcomes (PROs) and quality of life|To investigate the plasma PK of ZN-c3 and niraparib when given in combination - Maximum Plasma Concentration|To investigate the plasma PK of ZN-c3 and niraparib when given in combination - Area under the plasma concentration-time curve from 0 to 24h|To investigate the plasma PK of ZN-c3 and niraparib when given in combination - Trough concentration|To investigate the plasma PK of ZN-c3 and niraparib when given in combination - Time to maximum plasma concentration | K-Group Beta | Female | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 138 | Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | ZN-c3-006|GOG-3067|2021-004161-13 | January 2022 | November 2023 | November 2023 | January 20, 2022 | January 20, 2022 | https://ClinicalTrials.gov/show/NCT05198804 | ||||
| 11 | 11 | NCT04729608 | AVB-S6-500 (Batiraxcept)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer | AXLerate-OC | Recruiting | No Results Available | Platinum-resistant Ovarian Cancer | Drug: Batiraxcept|Drug: Paclitaxel|Other: Placebo | Anti-tumor activity of AVB-S6-500 in combination with Pac measured by progression free survival (PFS) in patients receiving AVB-S6-500 + Pac versus patients receiving Placebo+Pac|Overall survival | Aravive, Inc.|GOG Foundation|European Network of Gynaecological Oncological Trial Groups (ENGOT) | Female | 18 Years and older (Adult, Older Adult) | Phase 3 | 400 | Industry|Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment | AVB500-OC-004|GOG-3059|ENGOT OV66|AXLerate-OC | April 22, 2021 | July 2023 | July 2024 | January 28, 2021 | December 29, 2021 | University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States|Disney Family Cancer Center, Burbank, California, United States|Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States|UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange, California, United States|Stanford Women's Cancer Center, Palo Alto, California, United States|Olive View UCLA Medical Center, Sylmar, California, United States|Banner MD Anderson Cancer Center/North Colorado Medical Center, Greeley, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Georgia Cancer Center at Augusta University, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Dr. Sudarshan K. Sharma, Ltd., Hinsdale, Illinois, United States|Community Health Network, Indianapolis, Indiana, United States|St Vincent Hospital and Healthcare Center, Indianapolis, Indiana, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Women's Cancer Care, Covington, Louisiana, United States|Willis-Knighton Physician Network, Shreveport, Louisiana, United States|Maine Medical Partners - Women's Health - Division of Gynecologic Oncology, Scarborough, Maine, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Beth Israel Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Washington University School of Medicine - Division of Gynecologic Oncology, Saint Louis, Missouri, United States|Mercy Hospital, David C Pratt Cancer Center, Saint Louis, Missouri, United States|Billings Clinic, Billings, Montana, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Center of Hope, Reno, Nevada, United States|The Valley Hospital - Luckow Pavilion, Paramus, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Optimum Clinical Research Group, LLC, Albuquerque, New Mexico, United States|The Blavatnik Family-Chelsea Medical Center at Mount Sinai, New York, New York, United States|North Shore Hematology Oncology Assoc. DBA NY Cancer and Blood Specialists, Port Jefferson Station, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Duke Cancer Center, Durham, North Carolina, United States|First Health of the Carolinas, Pinehurst, North Carolina, United States|Miami Valley Hospital South, Centerville, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Columbus NCORP, Columbus, Ohio, United States|Kettering Cancer Center, Kettering, Ohio, United States|Stephenson Cancer Center - University of Oklahoma, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Providence Cancer Institute Franz Clinic, Portland, Oregon, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Chattanooga's Program in Women's Oncology, Chattanooga, Tennessee, United States|University of Tennessee, Knoxville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Carilion Clinic Gynecology Oncology, Roanoke, Virginia, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Pro Healthcare Waukesha Memorial Hospital, Waukesha, Wisconsin, United States | https://ClinicalTrials.gov/show/NCT04729608 | ||
| 12 | 12 | NCT04718376 | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer | Recruiting | No Results Available | Platinum-resistant Ovarian Cancer | Drug: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV) | adverse events (AEs)|overall response rate (ORR)|duration of response (DoR)|duration of complete response (DCR)|progression-free survival (PFS)|overall survival (OS) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Female | 18 Years and older (Adult, Older Adult) | Phase 1 | 30 | Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | HE071-CSP-015 | January 12, 2021 | January 11, 2022 | January 11, 2024 | January 22, 2021 | June 2, 2021 | Chongqing University Cancer Hospital, Chongqing, Chongqing, China|Fujian Cancer Hospital, Fuzhou, Fujian, China|Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China|Guizhou Cancer Hospital, Guiyang, Guizhou, China|Harbin Medical University Hospital, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China | https://ClinicalTrials.gov/show/NCT04718376 | |||
| 13 | 13 | NCT04376073 | Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer | ANNIE | Recruiting | No Results Available | Platinum-resistant Ovarian Cancer | Drug: Niraparib|Drug: Anlotinib | Objective Response Rate|The frequency and severity of adverse events|Progression-free survival|Objective tumor response | Jihong Liu|Sun Yat-sen University | Female | 18 Years to 70 Years (Adult, Older Adult) | Phase 2 | 40 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 2019-FXY-357 | May 22, 2020 | December 31, 2021 | March 31, 2022 | May 6, 2020 | November 25, 2020 | Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China | https://ClinicalTrials.gov/show/NCT04376073 | ||
| 14 | 14 | NCT01711970 | A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | Completed | No Results Available | Platinum Resistant Ovarian Cancer | Drug: Paclitaxel | Define toxicities | Vascular Biogenics Ltd. operating as VBL Therapeutics | Female | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 38 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | VB-111-157|11-418 | November 2012 | May 3, 2017 | May 3, 2017 | October 23, 2012 | April 24, 2020 | Massachusetts General Hospital, Boston, Massachusetts, United States | https://ClinicalTrials.gov/show/NCT01711970 | |||
| 15 | 15 | NCT02028117 | Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients | OCTAVE | Completed | No Results Available | Recurrent Platinum Resistant Ovarian Cancer | Biological: Enadenotucirev | Phase I - maximum tolerated dose | PsiOxus Therapeutics Ltd | Female | 18 Years and older (Adult, Older Adult) | Phase 1 | 38 | Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | ColoAd1-2001 | June 2014 | November 19, 2019 | November 19, 2019 | January 6, 2014 | May 13, 2021 | Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain|Clara Campal Comprehensive Cancer Center Hospital, Madrid, Spain|MD Anderson Cancer Center, Madrid, Spain|START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain|Hospital Miguel Servet, Zaragoza, Spain|The Royal Surrey County Hospital, Guildford, Surrey, United Kingdom|Beatson Institute, Glasgow, United Kingdom|The Christie Hospital, Manchester, United Kingdom | https://ClinicalTrials.gov/show/NCT02028117 | ||
| 16 | 16 | NCT02608684 | A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer | PemCiGem | Active, not recruiting | Has Results | Ovarian Cancer | Drug: Pembrolizumab|Drug: Gemcitabine|Drug: Cisplatin | Overall Response Rate (ORR)|Overall Response Rate by iRECIST|Progression-free Survival (PFS) at 6 Months and at 12 Months|Time to Progression|Duration of Response|Overall Survival (OS)|Frequency and Intensity of Adverse Events (CTCAE v.4), Deemed at Least Possibly Related to Study Participation | Cedars-Sinai Medical Center|Merck Sharp & Dohme Corp. | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 21 | Other|Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | IIT2015-13-Walsh-PemCiGem | February 8, 2016 | May 17, 2019 | December 2022 | November 20, 2015 | March 17, 2020 | October 26, 2021 | Cedars-Sinai Medical Center, Los Angeles, California, United States | "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02608684/Prot_SAP_000.pdf | https://ClinicalTrials.gov/show/NCT02608684 |
| 17 | 17 | NCT03146663 | NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer | Terminated | Has Results | Ovarian Cancer | Drug: NUC-1031 500 mg|Drug: NUC-1031 750mg | Best Overall Response | NuCana plc | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 53 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | PRO-105|2016-003287-39 | September 28, 2017 | December 31, 2019 | December 31, 2019 | May 10, 2017 | February 21, 2021 | February 21, 2021 | Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Rocky Mountain Cancer Centers, LLP, Lakewood, Colorado, United States|Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States|Minnesota Oncology Hematology, P.A., Edina, Minnesota, United States|SCRI - HCA Health Midwest, Kansas City, Missouri, United States|Nashville Tennessee Oncology, Nashville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|Texas Oncology The Woodlands, Gynecologic Oncology, The Woodlands, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|Edinburgh Cancer Centre, Edinburgh, United Kingdom|Cancer Research UK Clinical Trial Unit, Glasgow, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|University College London Hospital, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|Oxford University Hospital Foundation Trust, Oxford, United Kingdom | "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03146663/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03146663/SAP_001.pdf | https://ClinicalTrials.gov/show/NCT03146663 | |
| 18 | 18 | NCT03955471 | Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer | MOONSTONE | Active, not recruiting | No Results Available | Ovarian Neoplasms | Drug: Niraparib|Drug: Dostarlimab | Objective Response Rate (ORR)|Duration of Response (DOR)|Progression-free Survival (PFS)|Overall Survival (OS)|Disease Control Rate (DCR)|ORR Based on Independent Review Committee Assessment|DOR based on Independent Review Committee Assessment|PFS based on Independent Review Committee Assessment|DCR based on Independent Review Committee Assessment|Number of participants with adverse events (AEs), serious adverse events (SAEs) and adverse event of special interest (AESI)|Number of participants with clinically significant changes in vital signs, hematology, plasma chemistry, coagulation and thyroid function | Tesaro, Inc.|Gynecologic Oncology Group | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 41 | Industry|Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 213353|3000-02-006 | October 3, 2019 | August 18, 2021 | April 25, 2022 | May 20, 2019 | December 17, 2021 | GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Newport Beach, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Solvang, California, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Burlington, Massachusetts, United States|GSK Investigational Site, Maplewood, Minnesota, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Harrison, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Germantown, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, The Woodlands, Texas, United States|GSK Investigational Site, Charlottesville, Virginia, United States | https://ClinicalTrials.gov/show/NCT03955471 | ||
| 19 | 19 | NCT04633239 | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | Suspended | No Results Available | Recurrent High Grade Ovarian Serous Adenocarcinoma|Recurrent Platinum-Resistant Ovarian Carcinoma | Drug: Abemaciclib|Drug: Olaparib | Recommended phase 2 dose (RP2D)|Overall response rate (ORR)|Duration of response (DoR) | National Cancer Institute (NCI) | Female | 18 Years and older (Adult, Older Adult) | Phase 1 | 41 | NIH | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | NCI-2020-10084|10422|UM1CA186689 | February 12, 2021 | December 1, 2022 | December 1, 2022 | November 18, 2020 | December 6, 2021 | Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States | https://ClinicalTrials.gov/show/NCT04633239 | |||
| 20 | 20 | NCT03281681 | A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer | REPROVe | Withdrawn | No Results Available | Ovarian Cancer | Drug: VAL-083, Dianhydrogalactitol | Estimate Overall Response Rate|Safety evaluation of VAL-083 for adverse events|Efficacy evaluation of VAL-083 against CA-125 biomarker|Progression-free Survival|Comparative Progression-free Survival|Duration of Response|Overall Survival|Cmax|Tmax|AUClast|AUCinf|Lambda z|T 1/2|Quality of Life | DelMar Pharmaceuticals, Inc.|Kintara Therapeutics, Inc. | All | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 0 | Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | DLM-17-001 | March 2021 | March 2022 | September 2022 | September 13, 2017 | October 18, 2019 | St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States | https://ClinicalTrials.gov/show/NCT03281681 | ||
| 21 | 21 | NCT03742713 | Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer | CINOVA | Completed | No Results Available | Cancer|Ovarian Cancer | Drug: CPC634 (CriPec® docetaxel) | Objective Response Rate (ORR)|Incidence of Treatment-Emergent Adverse Events (safety and tolerability)|Progression free survival|GCIG CA-125 response criteria|Duration of response (DOR)|Time to progression (TTP)|Disease control rate (DCR) | Cristal Therapeutics | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 25 | Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | CT-CL02 | October 1, 2018 | December 1, 2020 | December 1, 2020 | November 15, 2018 | December 28, 2020 | Universitaire Ziekenhuizen Leuven, Leuven, Belgium|CHU de Liège, Liège, Belgium|University Medical Center Groningen, Groningen, Netherlands|Dijklander Hospital, Hoorn, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands|Viecuri Medical Center, Venlo, Netherlands|UCL Cancer Institute, London, United Kingdom | https://ClinicalTrials.gov/show/NCT03742713 | ||
| 22 | 22 | NCT03117933 | Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | OCTOVA | Active, not recruiting | No Results Available | Ovarian Cancer | Drug: Olaparib|Drug: Cediranib|Drug: Paclitaxel | Progression free survival|Adverse events|Overall Survival|Objective Response Rate|Quality of Life Outcomes | University of Oxford|AstraZeneca | Female | 16 Years and older (Child, Adult, Older Adult) | Phase 2 | 139 | Other|Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | OCTO_062|2016-000559-28|16/LO/2150 | March 9, 2017 | March 12, 2021 | November 30, 2021 | April 18, 2017 | July 8, 2021 | Belfast City Hospital, Belfast, County Antrim, United Kingdom|Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom|City Hospital Nottingham, Nottingham, Nottinghamshire, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, United Kingdom|Royal United Hospital, Bath, United Kingdom|Velindre, Cardiff, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Clatterbridge Cancer Centre, Liverpool, United Kingdom|St Bartholomew's, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Royal Marsden Chelsea & Sutton, London, United Kingdom|University College London, London, United Kingdom|The Christie, Manchester, United Kingdom|Churchill Hospital, Oxford, United Kingdom | https://ClinicalTrials.gov/show/NCT03117933 | ||
| 23 | 23 | NCT00102622 | Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer | Terminated | No Results Available | Ovarian Cancer | Biological: Intraperitoneal tgDCC-E1A|Drug: Paclitaxel | Maximum Tolerated Dose (MTD) of Intraperitoneal (IP) tgDCC-E1A in combination with Intravenous (IV) Paclitaxel|Tumor response of intraperitoneal (IP) tgDCC-E1A in combination with intravenous (IV) paclitaxel compared to IV paclitaxel alone | M.D. Anderson Cancer Center|National Institutes of Health (NIH)|National Cancer Institute (NCI) | Female | 18 Years and older (Adult, Older Adult) | Phase 1 | 18 | Other|NIH | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | ID02-321|P50CA083639 | December 1, 2004 | July 2012 | July 2012 | February 1, 2005 | November 13, 2018 | University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States | https://ClinicalTrials.gov/show/NCT00102622 | |||
| 24 | 24 | NCT01202890 | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | Terminated | No Results Available | Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma | Drug: Lenalidomide, Liposomal Doxorubicin, Bevacizumab|Drug: Revlimid, Doxil, Avastin | Maximum Tolerated Dose (MTD) of the 3 drug combination and recommend a dose for phase II studies.|Progression-free survival (PFS) after treatment with Revlimid plus Avastin and Doxil.|Acute and subacute toxicities of Lenalidomide plus Doxil and Avastin for the treatment of ovarian cancer. | New Mexico Cancer Care Alliance|Celgene Corporation | Female | Child, Adult, Older Adult | Phase 1 | 1 | Other|Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | INST 1001 | September 2010 | May 2011 | May 2012 | September 16, 2010 | January 8, 2014 | University of New Mexico Cancer Center, Albuquerque, New Mexico, United States | https://ClinicalTrials.gov/show/NCT01202890 | |||
| 25 | 25 | NCT00831636 | A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer | Completed | No Results Available | Ovarian Cancer | Drug: CP-4055 | Phase I: Determine recommended dose for phase II studies of CP-4055 when given five consecutive days twice in a 4 week schedule, D1-5 and D8(+2)-12(+2) q4w|Phase II: Determine the antitumour activity of CP-4055|Determine pharmacokinetic (PK) parameters|Explore the time to progression (TTP)|Investigate the duration of tumour response|Determine the nature and degree of toxicity of CP-4055 in this patient population | Clavis Pharma | Female | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 28 | Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | CP4055-204 | April 2008 | November 2009 | April 2010 | January 29, 2009 | September 13, 2013 | U.Z. Gasthuisberg, Gynecologic Oncology, Herestraat 49, Leuven, Belgium|Medical Oncology C, National Cancer Institute, Centro di Riferimento Oncologico, Aviano (PN), Italy|Medical Oncology B, National Cancer Institute, Via Mariano Semmola, Naples, Italy|Department of Oncology, Catholic University of the Sacred Heart, Rome, Italy|Medical Oncology, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy | https://ClinicalTrials.gov/show/NCT00831636 | |||
| 26 | 26 | NCT02421588 | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients | CORAIL | Completed | Has Results | Ovarian Cancer | Drug: Lurbinectedin (PM01183)|Drug: Pegylated liposomal doxorubicin (PLD)|Drug: Topotecan | Progression-free Survival by Independent Review Committee|Progression-free Survival by Investigator's Assessment|Overall Survival (OS)|Overall Response Rate (ORR) by Independent Review Committee|Overall Response Rate by Investigator's Assessment|Duration of Response by Independent Review Committee|Duration of Response by Investigator's Assessment|Best Response According to Tumor Marker Evaluation (CA-125) | PharmaMar | All | 18 Years and older (Adult, Older Adult) | Phase 3 | 442 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | PM1183-C-004-14 | May 2015 | October 12, 2018 | October 12, 2018 | April 20, 2015 | March 5, 2020 | April 3, 2020 | 1112, Peoria, Arizona, United States|1102, Greenbrae, California, United States|1103, La Jolla, California, United States|1116, Los Angeles, California, United States|1120, Los Angeles, California, United States|1113, Palo Alto, California, United States|1111, San Francisco, California, United States|1122, Santa Maria, California, United States|1123, West Hills, California, United States|1109, Augusta, Georgia, United States|1104, Indianapolis, Indiana, United States|1110, Covington, Louisiana, United States|1124, Scarborough, Maine, United States|1121, Brick, New Jersey, United States|1127, Albany, New York, United States|1105, New York, New York, United States|1117, Asheville, North Carolina, United States|1101, Charlotte, North Carolina, United States|1125, Charlotte, North Carolina, United States|1108, Durham, North Carolina, United States|1107, Columbus, Ohio, United States|1118, Dayton, Ohio, United States|1119, Pittsburgh, Pennsylvania, United States|1115, Greenville, South Carolina, United States|1129, Nashville, Tennessee, United States|1131, Fort Worth, Texas, United States|1128, Houston, Texas, United States|1106, Charlottesville, Virginia, United States | "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02421588/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02421588/SAP_001.pdf | https://ClinicalTrials.gov/show/NCT02421588 |
| 27 | 27 | NCT03657043 | A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) | Active, not recruiting | No Results Available | Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer | Drug: tisotumab vedotin | Incidence of dose limiting toxicities (DLTs) (Safety Run-in only)|Confirmed objective response rate (ORR) (Parts A and B)|Incidence of adverse events that are Grade 3+, treatment-related, or serious (Parts A and B)|Confirmed and unconfirmed ORR (Parts A and B)|Cancer Antigen 125 (CA-125) response rate according to Gynecologic Cancer Intergroup (GCIG) criteria (Parts A and B)|Overall response according to the Gynecological Cancer Intergroup (GCIG) combined RECIST and CA-125 criteria (Parts A and B)|Duration of response (DOR) (Parts A and B)|Disease control rate (DCR) (Parts A and B)|Time to response (TTR) (Parts A and B)|Progression-free survival (PFS) (Parts A and B)|Overall survival (OS) (Parts A and B)|Pharmacokinetic (PK) parameter: Cmax (Parts A and B)|PK parameter: AUClast (Parts A and B)|Incidence of antitherapeutic antibodies (ATA) (Parts A and B) | Seagen Inc.|Genmab | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 98 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | SGNTV-002 | March 20, 2019 | August 31, 2022 | August 31, 2022 | September 4, 2018 | February 1, 2022 | Stanford Cancer Center South Bay, San Jose, California, United States|Poudre Valley Health System (PVHS), Fort Collins, Colorado, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|Miami Cancer Institute- Plantation (MCIP), Miami, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Augusta University, Augusta, Georgia, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States|University of Missouri Healthcare / Ellis Fischel Cancer Center, Columbia, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mount Sinai Chelsea, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic, The, Cleveland, Ohio, United States|Ohio State University Clinical Trials Management Office, Columbus, Ohio, United States|Cleveland Clinic Hillcrest Hospital, Mayfield Heights, Ohio, United States|Texas Oncology - Fort Worth, Dallas, Texas, United States|Renovatio Clinical, The Woodlands, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Algemeen Ziekenhuis Maria Middelares, Ghent, Other, Belgium|Universitair Ziekenhuis Leuven, Lueven, Other, Belgium|Aalborg Universite Hospital, Aalborg, Other, Denmark|Mater Private, Dublin, Other, Ireland|Cork University Hospital, Wilton, Other, Ireland|Ospedale Ramazzini di Carpi, Carpi, Other, Italy|IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"- IRST S.r.l, Meldola, Other, Italy|Istituto Europeo di Oncologia, Milano, Other, Italy|Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Other, Italy|Fondazione Policlinico Universitario Agostino, Rome, Other, Italy|Hospital Universitario Vall d'Hebron, Barcelona, Other, Spain|Institut Catala D'Oncologia Hospitalet, Barcelona, Other, Spain|Hospital Universitario Ramon y Cajal, Madrid, Other, Spain|HM Centro Integral Oncologico Clara Campal, Madrid, Other, Spain|Clinica Universidad de Navarra, Pamplona, Other, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón, Other, Spain | https://ClinicalTrials.gov/show/NCT03657043 | |||
| 28 | 28 | NCT02545010 | Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer | Unknown status | No Results Available | Ovarian Cancer | Drug: Paclitaxel|Radiation: LDWART (Low Dose Whole Abdominal Radiation Therapy) | Maximal tolerated dose (MTD) of weekly paclitaxel in combination with LDWART|Objective response rate (ORR)|Progression Free Survival (PFS)|Dose limiting toxicity (DLT) | National University Hospital, Singapore | Female | 21 Years and older (Adult, Older Adult) | Phase 1 | 24 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | GY01/05/15|2015/00496 | September 2015 | August 2017 | August 2018 | September 9, 2015 | June 22, 2016 | National University Hospital, Singapore, Singapore | https://ClinicalTrials.gov/show/NCT02545010 | |||
| 29 | 29 | NCT00722592 | Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) | PRECEDENT | Completed | No Results Available | Ovarian Cancer | Drug: Vintafolide|Drug: pegylated liposomal doxorubicin (PLD)|Other: EC20 | Progression-free survival based on investigator assessment using RECIST and clinical findings|Compare overall survival of subjects between the two treatment arms|Evaluate the safety and tolerability of EC145 in combination with PLD|Compare objective response rate (ORR) and duration of response of EC145 in combination with PLD, versus PLD alone, based on investigator assessment when analyzed using RECIST.|Explore the correlation between therapeutic response (e.g. PFS, radiologic response, etc) and 99mTc-EC20 levels | Endocyte | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 162 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 8109-009|EC-FV-04 | September 2008 | September 2010 | December 2012 | July 25, 2008 | January 7, 2015 | https://ClinicalTrials.gov/show/NCT00722592 | |||
| 30 | 30 | NCT03804866 | NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) | Completed | No Results Available | Ovarian Cancer | Drug: NGR-hTNF|Drug: Pegylated liposomal doxorubicin|Drug: Doxorubicin | Safety according to NCI-CTCAE criteria (version 4.03)|Progression-Free Survival (PFS)|Overall survival (OS)|Response Rate (RR)|Disease Control Rate (DCR)|Duration of Disease Control | AGC Biologics S.p.A. | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 14 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | NGR018-IPR/26|2012-005745-20 | March 2013 | December 2016 | December 2016 | January 15, 2019 | January 15, 2019 | Ospedale San Raffaele, Milan, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Istituto Europeo di Oncologia, Milan, Italy|Istituto Nazionale Tumori IRCCS Fondazione "Giovanni Pascale", Naples, Italy | https://ClinicalTrials.gov/show/NCT03804866 | |||
| 31 | 31 | NCT01639885 | Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer | CHIP | Completed | No Results Available | Recurrent Ovarian Cancer | Drug: Interferon Alfa-2b|Biological: p53 SLP | Feasibility (change in grade III and IV toxicity) and change in immunogenicity of the triple combination of gemcitabine, Peg-Intron and p53 SLP vaccination|Clinical outcome (response (RECIST 1.1)|The effect of this new treatment combination on the immune system|progression free survival|overall survival | Leiden University Medical Center|University Medical Center Groningen | Female | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 15 | Other | Interventional | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | CHIP trial|2010-023124-24 | August 2011 | January 2014 | July 13, 2012 | January 7, 2014 | Leiden University Medical Center, Leiden, Netherlands | https://ClinicalTrials.gov/show/NCT01639885 | |||
| 32 | 32 | NCT02431559 | Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | Completed | Has Results | Ovarian Cancer | Drug: Durvalumab|Drug: Pegylated Liposomal Doxorubicin|Drug: Motolimod | Number of Subjects With Treatment-emergent Adverse Events (TEAEs)|Progression-free Survival Rate at 6 Months (PFS-6) by the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Estimated Using the Kaplan-Meier Method|Number of Subjects With Best Overall Tumor Response by RECIST 1.1|Median PFS by RECIST 1.1 as Estimated Using the Kaplan-Meier Method|PFS-12 by RECIST 1.1 as Estimated Using the Kaplan-Meier Method|Number of Subjects With Best Overall Tumor Response by the Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)|PFS-6 by irRECIST as Estimated Using the Kaplan-Meier Method|PFS-12 by irRECIST as Estimated Using the Kaplan-Meier Method|Median PFS by irRECIST as Estimated Using the Kaplan-Meier Method|Median Overall Survival (OS) as Estimated Using the Kaplan-Meier Method | Ludwig Institute for Cancer Research|MedImmune LLC|Celgene|Cancer Research Institute, New York City | Female | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 53 | Other|Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | LUD2014-001 | December 2, 2015 | December 11, 2018 | June 10, 2021 | May 1, 2015 | September 23, 2019 | September 5, 2021 | Research Facitlity, Phoenix, Arizona, United States|Research Facility, New York, New York, United States|Research Facility, Hilliard, Ohio, United States|Research Facility, Providence, Rhode Island, United States|Research Facility, Lausanne, Switzerland | "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02431559/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02431559/SAP_001.pdf | https://ClinicalTrials.gov/show/NCT02431559 | |
| 33 | 33 | NCT02764333 | TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer | Completed | Has Results | Ovarian Cancer | Biological: TPIV200|Biological: Durvalumab | Overall Response Rate | Memorial Sloan Kettering Cancer Center|AstraZeneca|Marker Therapeutics, Inc. | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 29 | Other|Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 16-011 | May 6, 2016 | January 20, 2021 | January 20, 2021 | May 6, 2016 | November 30, 2021 | November 30, 2021 | Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center at Rockville, Rockville Centre, New York, United States | "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02764333/Prot_SAP_000.pdf | https://ClinicalTrials.gov/show/NCT02764333 | |
| 34 | 34 | NCT01170650 | Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) | PROCEED | Terminated | No Results Available | Ovarian Cancer | Drug: EC145|Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)|Drug: placebo|Drug: EC20 | Progression-free survival based on investigator assessment using RECIST v1.1.|Compare overall survival of participants between treatment arms.|Incidence of Adverse Events, Serious Adverse Events, and Deaths. | Endocyte | Female | 18 Years and older (Adult, Older Adult) | Phase 3 | 441 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | 8109-002|EC-FV-06 | April 22, 2011 | May 31, 2015 | September 8, 2015 | July 27, 2010 | September 30, 2021 | https://ClinicalTrials.gov/show/NCT01170650 | |||
| 35 | 35 | NCT01469793 | A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer | Completed | No Results Available | Ovarian Cancer | Drug: DMOT4039A | Maximum Tolerated Dose (MTD) of DMOT4039A|Number of Participants With Dose-Limiting Toxicities (DLTs)|Recommended Phase 2 Dose (RP2D) of DMOT4039A|Area Under the Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC [0-inf]) of DMOT4039A Total Antibody|AUC (0-inf) of Antibody-Conjugated Monomethyl Auristatin E (acMMAE)|AUC (0-inf) of Unconjugated MMAE|Maximum Observed Concentration (Cmax) of DMOT4039A Total Antibody|Cmax of acMMAE|Cmax of Unconjugated MMAE|Total Clearance (CL) of DMOT4039A Total Antibody|CL of acMMAE|Half-life (t1/2) of DMOT4039A Total Antibody|t1/2 of acMMAE|t1/2 of Unconjugated MMAE|Volume of Distribution at Steady State (Vss) of DMOT4039A Total Antibody|Vss of acMMAE|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs)|Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Duration of Objective Response (DOR) According to RECIST v1.1|Progression-free Survival (PFS) According to RECIST v1.1 | Genentech, Inc. | All | 18 Years and older (Adult, Older Adult) | Phase 1 | 71 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | DMO4993g|GP27896|2011-002713-10 | November 2011 | December 2015 | December 2015 | November 10, 2011 | January 10, 2017 | Phoenix, Arizona, United States|Aurora, Colorado, United States|Jacksonville, Florida, United States|Rochester, Minnesota, United States|Amsterdam, Netherlands|Groningen, Netherlands | https://ClinicalTrials.gov/show/NCT01469793 | |||
| 36 | 36 | NCT00408603 | Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer | Completed | Has Results | Epithelial Ovarian Cancer | Drug: Voreloxin Injection | Overall Response Rate (CR+PR) Per Investigator Assessment Based on GOG-RECIST Criteria|Progression-free Survival (PFS) Using Kaplan-Meier Methods | Sunesis Pharmaceuticals | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 183 | Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | SPO-0010 | December 20, 2006 | June 9, 2010 | June 9, 2010 | December 7, 2006 | June 28, 2017 | July 27, 2017 | Premiere Oncology of Arizona, Scottsdale, Arizona, United States|Gynecologic Oncology Associates, Newport Beach, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Stanford University, Stanford, California, United States|Medstar Research Institute at Washington Hospital Center, Washington, D.C., District of Columbia, United States|Oncology Specialists, S.C. at Luthern General Advanced Care Center, Park Ridge, Illinois, United States|Louisville Oncology Clinical Research Program, Louisville, Kentucky, United States|The Harry and Jeanette Weinberg Institute at Franklin Square, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, United States|Kaiser Permanente NW Region, Portland, Oregon, United States|University of Pittsburgh Medical Center at Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States|Hall and Martin, MD's, P.C., Knoxville, Tennessee, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|BC Cancer Agency at Centre for Southern Interior, Kelowna, British Columbia, Canada|BC Cancer Agency at Fraser Valley Centre, Surrey, British Columbia, Canada|BC Cancer Agency at Vancouver, Vancouver, British Columbia, Canada|BC Cancer Agency - Vancouver Island Centre, Victoria, British Columbia, Canada|Juravinski Cancer Centre Department of Oncology, Hamilton, Ontario, Canada | https://ClinicalTrials.gov/show/NCT00408603 | ||
| 37 | 37 | NCT03539328 | Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer | MITO27 | Not yet recruiting | No Results Available | Ovarian Cancer | Drug: Pembrolizumab|Drug: Gemcitabine|Drug: Paclitaxel|Drug: Liposomal Doxorubicin | Overall survival (OS)|Progression free survival (PFS)|Response rate|Adverse events|Exploratory Objective: relationship between PD-L1 expression and response to Pembrolizumab treatment.|Exploratory Objective: association between anti-tumor activity from genetic alterations that may indicate a specific genotype reflective of greater dependency on PD-1/PD-L1 checkpoint function or other immune checkpoint signaling pathways|Quality of life | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 138 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 180-17 | June 2018 | April 2022 | April 2022 | May 29, 2018 | May 29, 2018 | National Cancer Institute, Milan, Italy | https://ClinicalTrials.gov/show/NCT03539328 | ||
| 38 | 38 | NCT01991210 | A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) | Terminated | No Results Available | Ovarian Cancer | Drug: DNIB0600A|Drug: PLD | Progression-free Survival According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Percentage of Participants With Objective Response According to RECIST v1.1|Duration of Objective Response|Overall Survival (OS)|Percentage of Participants With Adverse Events (AEs)|Area Under the Concentration-time Curve (AUC) of DNIB0600A|Maximum Concentration (Cmax) of DNIB0600A|Clearance (CL) of DNIB0600A|Elimination Half-life (t1/2) of DNIB0600A|Volume of Distribution at Steady State (Vss) of DNIB0600A|Percentage of Participants With Anti-therapeutic Antibodies (ATAs) Against DNIB0600A | Genentech, Inc. | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 95 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | GO28609|2012-005776-34 | February 6, 2014 | August 17, 2016 | August 17, 2016 | November 25, 2013 | August 21, 2017 | St. Joseph'S Hospital & Medical Center, Phoenix, Arizona, United States|HonorHealth Research Institute - Pima Center, Scottsdale, Arizona, United States|University of California Irvine Medical Center, Orange, California, United States|Florida Cancer Specialists., Saint Petersburg, Florida, United States|Hematology & Oncology Associates, Covington, Louisiana, United States|Johns Hopkins Uni; Oncology Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Inst., Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Women & Infants Hospital, Providence, Rhode Island, United States|Sarah Cannon Cancer Center, Germantown, Tennessee, United States|UZ Leuven Gasthuisberg, Leuven, Belgium|CHU Sart-Tilman, Liège, Belgium|London Regional Cancer Centre, London, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Chum Hopital Notre Dame; Centre D'Oncologie, Montreal, Quebec, Canada|Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes, Lyon, France|Hôpital Européen Georges Pompidou, Paris, France|HOPITAL TENON; Cancerologie Medicale, Paris, France|Institut Gustave Roussy, Villejuif, France|Bialostockie Centrum Onkologi, Bialystok, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Wojskowy Instytut Medyczny Centralny Szpital Kliniczny MON, Warszawa, Poland|Hospital Universitario Vall d'Hebron; Servicio de Neumologia, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Sarah Cannon Research Institute, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom | https://ClinicalTrials.gov/show/NCT01991210 | |||
| 39 | 39 | NCT01358071 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer | NGR018 | Completed | No Results Available | Ovarian Cancer | Drug: NGR-hTNF|Drug: Pegylated liposomal doxorubicin|Drug: Doxorubicin | Progression-Free Survival (PFS)|Overall survival (OS)|Response Rate (RR)|Disease Control Rate (DCR)|Duration of Disease Control|Safety and Toxicity according to NCI-CTCAE criteria (version 4.03) | AGC Biologics S.p.A. | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 119 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | NGR018|2010-023613-61 | June 2011 | December 2016 | December 2016 | May 23, 2011 | September 27, 2018 | Ospedale San Raffaele, Milan, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Istituto Europeo di Oncologia, Milan, Italy|Istituto Nazionale Tumori IRCCS Fondazione "Giovanni Pascale", Naples, Italy|Ospedale S. Maria della Misericordia, Perugia, Italy|Policlinico Universitario "Agostino Gemelli", Rome, Italy|Beatson Oncology Centre, Gartnavel Hospital, Glasgow, Scotland, United Kingdom|Clatterbridge Centre for Oncology, Bebington, Wirral, United Kingdom | https://ClinicalTrials.gov/show/NCT01358071 | ||
| 40 | 40 | NCT01335958 | Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer | Completed | No Results Available | Ovarian Cancer, Pancreatic Cancer | Drug: DMUC5754A | Incidence of dose-limiting toxicities (DLTs)|Nature of dose-limiting toxicities (DLTs) graded per NCI CTCAE v4.0|Incidence of adverse events|Nature of adverse events graded per NCI CTCAE v4.0|Severity of adverse events|Area under the concentration-time curve|Maximum concentrations|Minimum concentrations|Clearance|Half-life|Volume of distribution | Genentech, Inc. | All | 18 Years and older (Adult, Older Adult) | Phase 1 | 77 | Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | DGR4980g|GO00766 | April 2011 | February 2014 | February 2014 | April 15, 2011 | November 2, 2016 | Boston, Massachusetts, United States|Boston, Massachusetts, United States|Oklahoma City, Oklahoma, United States|Nashville, Tennessee, United States | https://ClinicalTrials.gov/show/NCT01335958 | |||
| 41 | 41 | NCT02146313 | A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer | Completed | No Results Available | Pancreatic Neoplasms|Ovarian Neoplasms | Drug: DMUC4064A | Percentage of Participants with Dose-Limiting Toxicities (DLTs)|Maximum Tolerated Dose of DMUC4064A|Recommended Part II Dose of DMUC4064A|Percentage of Participants with Adverse Events (AEs) or Serious Adverse Events (SAEs)|Percentage of Participants with Anti-DMUC4064A Antibodies|Pharmacokinetic (PK) Profile of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer|Percentage of Participants With Objective Response as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Duration of Objective Response|Progression-free Survival (PFS) as Assessed by RECIST v1.1 | Genentech, Inc. | All | 18 Years and older (Adult, Older Adult) | Phase 1 | 35 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | GO29213 | June 22, 2014 | June 18, 2018 | June 18, 2018 | May 23, 2014 | June 21, 2018 | Florida Cancer Specialists - Sarasota (North Catttlemen Rd), Sarasota, Florida, United States|Massachusetts General Hospital., Boston, Massachusetts, United States|Dana Farber Cancer Inst., Boston, Massachusetts, United States|Hackensack Univ Med Ctr, Hackensack, New Jersey, United States|Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States|Sarah Cannon Research Inst., Nashville, Tennessee, United States|University of Wisconsin, Madison, Wisconsin, United States | https://ClinicalTrials.gov/show/NCT02146313 | |||
| 42 | 42 | NCT01363947 | Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer | Completed | No Results Available | Non-Small Cell Lung Cancer, Ovarian Cancer | Drug: DNIB0600A | Percentage of Participants With Adverse Events (AEs)|Cmax of DNIB0600A for Antibody-Conjugated Monomethyl Auristatin E (acMMAE), Total Antibody, and Unconjugated Monomethyl Auristatin E (MMAE)|Percentage of Participants with Antibody Formation to DNIB0600A|Percentage of Participants with Objective Response (OR)|Duration of Objective Response (DOR) | Genentech, Inc. | All | 18 Years and older (Adult, Older Adult) | Phase 1 | 87 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | DNB4987g|GO27767|2014-000527-25 | June 14, 2011 | June 3, 2016 | June 3, 2016 | June 2, 2011 | June 7, 2017 | HonorHealth Research Institute - Pima Center, Scottsdale, Arizona, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Sarah Cannon Research Inst., Nashville, Tennessee, United States|Univ of Texas SW Medical Ctr, Dallas, Texas, United States|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain | https://ClinicalTrials.gov/show/NCT01363947 | |||
| 43 | 43 | NCT01494012 | Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer | Terminated | No Results Available | Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Malignant Tumor of Peritoneum|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor | Radiation: stereotactic body radiation therapy|Procedure: positron emission tomography|Procedure: computed tomography|Other: questionnaire administration|Drug: fludeoxyglucose F 18 | Tumor response to SBRT as assessed by FDG-PET/CT|The rate of grade 3 or greater non-hematologic acute toxicity as graded by the CTCAE v. 4.0|Measure CA-125 level|FACT-Ovarian Symptom Index|Late toxicity and non-grade 3 or greater acute toxicity following SBRT|Local control|Progression-free survival|Overall survival | Stanford University | Female | 18 Years and older (Adult, Older Adult) | Phase 1 | 1 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | GYNOVA0021|NCI-2011-03652|SU-12072011-8791|22550 | April 2012 | September 2012 | September 2012 | December 16, 2011 | April 28, 2017 | Stanford University, Stanford, California, United States | https://ClinicalTrials.gov/show/NCT01494012 | |||
| 44 | 44 | NCT00183794 | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | Completed | Has Results | Ovarian Carcinoma|Peritoneal Neoplasms | Drug: Docetaxel and Gemcitabine | Tumor Response Type: CR, PR, SD or PD|Median Time to Progression (Months) | University of Southern California|Aventis Pharmaceuticals|Eli Lilly and Company | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 20 | Other|Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 5GYN-02-2 | November 2002 | May 2009 | May 2010 | September 16, 2005 | January 25, 2013 | May 22, 2014 | Norris Comprehensive Cancer Center, Los Angeles, California, United States | https://ClinicalTrials.gov/show/NCT00183794 | ||
| 45 | 45 | NCT03663712 | Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies | TEMPO | Recruiting | No Results Available | Stage IV Peritoneal Surface Dissemination From Gastrointestinal or Recurrent, Platinum-resistant Ovarian Cancer That Cannot be Completely Resected | Biological: Talimogene Laherparepvec | Most Tolerable Dose (MTD) for talimogene laherparepvec|Non-dose limiting toxicities for talimogene laherparepvec | Dan Blazer III, M.D.|Duke University | All | 18 Years to 99 Years (Adult, Older Adult) | Phase 1 | 24 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | Pro00086917 | May 9, 2019 | March 1, 2022 | March 1, 2022 | September 10, 2018 | October 21, 2021 | University of Illinois College of Medicine at Chicago, Chicago, Illinois, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States | https://ClinicalTrials.gov/show/NCT03663712 | ||
| 46 | 46 | NCT04787289 | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer | Not yet recruiting | No Results Available | Ovarian Cancer|Platinum-resistant Ovarian Cancer | Drug: Bevacizumab | progression-free survival|Overall survival|Duration of response|Compare treatment-emergent grade 3-5 AEs|Quality of Life changes|Estimate drug cost savings | British Columbia Cancer Agency | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 244 | Other | Interventional | Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | BEV-DOSE | September 2021 | January 31, 2023 | January 31, 2025 | March 8, 2021 | July 21, 2021 | Abbotsford Centre, BC Cancer Agency, Abbotsford, British Columbia, Canada | https://ClinicalTrials.gov/show/NCT04787289 | |||
| 47 | 47 | NCT03542669 | Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer | Recruiting | No Results Available | Recurrent Ovarian Carcinoma|Platinum-resistant Ovarian Cancer | Drug: 6B11-OCIK Injection|Drug: Doxorubicin | MTD|Changes of the cell immunophenotype|Changes of the antinuclear antibody (ANA)|Changes of the C-reactive protein (CRP)|Changes of the interleukin-6 (IL-6)|Changes of the immunoglobulin|Objective response rate (ORR)|Disease control rate (DCR)|Progression Free Survival (PFS)|Correlation between OC166-9 antigen expression and efficacy of 6B11-OCIK injection. | Peking University People's Hospital | Female | 18 Years to 70 Years (Adult, Older Adult) | Phase 1 | 9 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 6B11-OCIK-I | August 3, 2018 | December 30, 2022 | December 30, 2023 | May 31, 2018 | December 2, 2021 | Peking University People's hospital, Beijing, China | https://ClinicalTrials.gov/show/NCT03542669 | |||
| 48 | 48 | NCT00429559 | Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma | Completed | No Results Available | Ovarian Cancer | Drug: Hycamptin|Drug: Gemcitabine | Determine the maximum tolerated dose and the response rate of gemcitabine plus topotecan.|Toxicity profile | Hellenic Oncology Research Group|University Hospital of Crete | Female | 18 Years to 75 Years (Adult, Older Adult) | Phase 1|Phase 2 | 31 | Other | Interventional | Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | CT/06.14 | June 2006 | July 2011 | July 2011 | January 31, 2007 | July 22, 2011 | University Hospital of Crete, Heraklion, Crete, Greece|University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece|"IASO" General Hospital of Athnes, Dep of Medical Oncology, Athens, Greece|"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece|State General Hospital of Larissa, Dep of Medical Oncology, Larissa, Greece|"Theagenion" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology, Thessaloniki, Greece | https://ClinicalTrials.gov/show/NCT00429559 | |||
| 49 | 49 | NCT03319628 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | Recruiting | No Results Available | Platinum Resistant Ovarian Cancer|Non Small Cell Lung Cancer Metastatic | Drug: upifitamab rilsodotin | DES: Maximum tolerated dose or recommended Phase 2 dose|DES and EXP: Safety and Tolerability|EXP: Anti-neoplastic effects of XMT-1536 (upifitamab rilsodotin)|UPLIFT: Investigator-assessed objective response rate (ORR) of XMT-1536 (upifitamab rilsodotin) in the ITT-Higher NaPi2b population|QTc Sub-study: Evaluation of the concentration response analysis of XMT-1536 versus the change in QTcF values|DES and EXP: Time of maximum observed concentration of XMT-1536 (upifitamab rilsodotin)|DES and EXP: Maximum concentration of XMT-1536 (upifitamab rilsodotin)|DES and EXP: Area under the concentration curve of the last measurable concentration of XMT-1536 (upifitamab rilsodotin)|DES: Anti-neoplastic effects of XMT-1536 (upifitamab rilsodotin)|DES and EXP: Anti-drug antibody and neutralizing antibody|UPLIFT: Investigator-assessed objective response rate of XMT-1536 (upifitamab rilsodotin) regardless of NaPi2b expression|UPLIFT: Objective response rate by independent radiology review (IRR) for patients with higher NaPi2b and overall|UPLIFT: Duration of objective response (DOR)|UPLIFT: Incidence and severity of adverse events|QTc Sub-Study: Evaluation of the effect of XMT-1536 on QTcF in patients with platinum-resistant HGSOC by timepoint analysis|QTc Sub-Study: Evaluation of the effect of XMT-1536 on the PR-interval (PR), QRS duration (QRS), Heart Rate (HR), and ECG morphology | Mersana Therapeutics|IQVIA Biotech | All | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 444 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | XMT-1536-1 | December 12, 2017 | April 30, 2023 | December 31, 2023 | October 24, 2017 | September 24, 2021 | University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Oncology Associates, Tucson, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|University of California - Irvine, Orange, California, United States|Sansum Clinic, Santa Barbara, California, United States|University of Colorado, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Miami - Miller School of Medicine, Miami, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Georgia Cancer Center at Augusta University, Augusta, Georgia, United States|Maryland Oncology and Hematology, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Insititute, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|QUEST Research Institute, Farmington Hills, Michigan, United States|START - Midwest, Grand Rapids, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Billings Clinic, Billings, Montana, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Southwest Women's Oncology- Optimum Clinical Research Group, Albuquerque, New Mexico, United States|Women's Cancer Care Associates, LLC, Albany, New York, United States|NYU Langone Health, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Kattering Medical Center, Kettering, Ohio, United States|Stephenson Cancer Centre-University of Oklahoma, Oklahoma City, Oklahoma, United States|Willamette Valley Cancer Institute, Eugene, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Institute of Transnational Oncology-Greenville Hospital System University Medical Center, Greenville, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|University of Tennessee, Knoxville, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology, Austin, Austin, Texas, United States|Texas Oncology-Austin, Austin, Texas, United States|Texas Oncology- Bedford, Bedford, Texas, United States|Mary Crowley Cancer Research Center, Dallas, Texas, United States|Texas Oncology Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, Fort Worth, Fort Worth, Texas, United States|Texas Oncology, Houston, Houston, Texas, United States|South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States|NEXT Oncology, San Antonio, Texas, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Virginia- Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|Virginia Cancer Specialist, Fairfax, Virginia, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|BlueRidge Cancer Care Physicians, Roanoke, Virginia, United States|Blacktown Hospital, Blacktown, New South Wales, Australia|Austin Health - Olivia Newton John Cancer Center, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Chris O'Brien Lifehouse, Camperdown, Australia|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|McGill University Health Centre - The Montreal General Hospital, Montreal, Quebec, Canada|Clinica Univ di Navarra, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain | https://ClinicalTrials.gov/show/NCT03319628 | |||
| 50 | 50 | NCT01104675 | Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer | Completed | No Results Available | Ovarian Cancer|Fallopian Cancer|Peritoneal Cancer | Drug: ENMD-2076 | Progression free survival rate | CASI Pharmaceuticals, Inc. | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 64 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 2076-CL-004 | April 2010 | August 2011 | December 2012 | April 15, 2010 | August 6, 2014 | University of Colorado Cancer Center, Aurora, Colorado, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Dana Farber/Partners Cancer Care, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Princess Margaret Hospital, Toronto, Ontario, Canada | https://ClinicalTrials.gov/show/NCT01104675 | |||
| 51 | 51 | NCT02575807 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer | SEASCAPE | Terminated | Has Results | Platinum-resistant Ovarian Cancer|Platinum-resistant Fallopian Cancer|Platinum-resistant Peritoneal Cancer | Biological: CRS-207|Drug: Epacadostat|Biological: Pembrolizumab | Phase 1: Number of Subjects Reporting Hematologic and/or Non-hematologic Dose-limiting Toxicity (DLT)|Phase 1: Adverse Events (AEs) by CTCAE Grade 3 or Higher|Phase 2: Adverse Events (AEs)|Phase 2: Objective Response Rate (ORR)|Phase 2: Progression Free Survival (PFS)|Phase 1: Objective Response Rate (ORR) by mRECIST|Phase 1: Progression Free Survival (PFS)|Disease Control Rate (DCR)|Duration of Response (DOR)|Overall Survival (OS) | Aduro Biotech, Inc.|Incyte Corporation | Female | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 35 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | ADU-CL-11 | March 8, 2016 | April 26, 2018 | May 8, 2018 | October 15, 2015 | April 4, 2019 | April 4, 2019 | Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, United States|Stanford Cancer Center, Stanford, California, United States|University of Florida, Gainesville, Florida, United States|Northwestern University, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM - Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada | "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02575807/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02575807/SAP_001.pdf | https://ClinicalTrials.gov/show/NCT02575807 |
| 52 | 52 | NCT04678102 | Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) | CREATIVE | Recruiting | No Results Available | Platinum-resistant Ovarian Cancer|Platinum-refractory Ovarian Carcinoma|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma | Drug: PHI-101 administration | Proportion of patients with dose-limiting toxicity (DLT)|Maximum tolerated dose|Dose interruption (temporary discontinuation) percent (%)|Dose reduction percent (%)|Dose termination (permanent discontinuation) percent (%)|Cmax|AUCt|AUCτ|AUCinf|Tmax|Tmax,ss|t1/2|PTF|AR|CL/F|CLss/F|Vdz/F|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DOR)|Progression-free survival (PFS)|Overall survival (OS)|Time to progression (TTP)|presence of genetic variation|Number of of adverse events | Seoul National University Hospital|Pharos iBio Co., Ltd. | Female | 19 Years and older (Adult, Older Adult) | Phase 1 | 36 | Other | Interventional | Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | PHI-101-002 | December 17, 2020 | December 31, 2021 | December 31, 2022 | December 21, 2020 | January 20, 2021 | Seoul National University Hospital, Seoul, Korea, Republic of | https://ClinicalTrials.gov/show/NCT04678102 | ||
| 53 | 53 | NCT03907527 | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Recruiting | No Results Available | Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Fallopian Tube Carcinoma|Refractory Ovarian Carcinoma|Refractory Primary Peritoneal Carcinoma|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IIIA Fallopian Tube Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Primary Peritoneal Cancer AJCC v8|Stage IIIA1 Fallopian Tube Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Fallopian Tube Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Fallopian Tube Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Primary Peritoneal Cancer AJCC v8|Stage IIIC Fallopian Tube Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8 | Biological: PRGN-3005 UltraCAR-T cells | Incidence of adverse events|Maximal tolerated dose of PRGN-3005|Evidence of anti-tumor activity | PGEN Therapeutics, Inc., a subsidiary of Precigen, Inc.|Precigen, Inc | Female | 18 Years and older (Adult, Older Adult) | Phase 1 | 71 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | RG1004303 | April 30, 2019 | December 15, 2023 | November 15, 2028 | April 9, 2019 | August 4, 2021 | Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States | https://ClinicalTrials.gov/show/NCT03907527 | |||
| 54 | 54 | NCT05092360 | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab | ARTISTRY-7 | Recruiting | No Results Available | Platinum-resistant Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer | Biological: Nemvaleukin and Pembrolizumab Combination|Biological: Pembrolizumab|Biological: Nemvaleukin|Drug: Pegylated Liposomal Doxorubicin (PLD)|Drug: Paclitaxel|Drug: Topotecan|Drug: Gemcitabine | Progression-free survival (PFS) as assessed by Investigator|Objective response rate as assessed by Investigator|Overall Survival Rate|Disease Control Rate (DCR) as assessed by Investigator|Duration of Response (DOR) as assessed by Investigator|Time to Response (TTR) as assessed by Investigator|Cancer antigen (CA)-125 response as defined by the Gynecologic Cancer InterGroup (GCIG)|Incidence of treatment-emergent adverse events (TEAEs) | Alkermes, Inc.|Merck Sharp & Dohme Corp. | Female | 18 Years and older (Adult, Older Adult) | Phase 3 | 376 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment | ALKS 4230-007|GOG-3063|ENGOT-OV68|KEYNOTE-C71 | January 2022 | December 2025 | December 2026 | October 25, 2021 | January 25, 2022 | Alkermes Investigator Site, Albany, New York, United States | https://ClinicalTrials.gov/show/NCT05092360 | ||
| 55 | 55 | NCT02090582 | H.O.P.E: Helping Ovarian Cancer Patients Cope | Completed | No Results Available | Platinum-resistant Ovarian Cancer|Recurrent Ovarian Cancer|Palliative Care | Other: Structured Palliative Care|Other: Usual Care | Quality of Life (Functional Assessment of Cancer Therapy for Ovarian Cancer and Functional Assessment of Chronic Illness Therapy for Palliative Care) | Duke University | Female | 18 Years and older (Adult, Older Adult) | Not Applicable | 47 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care | Pro00052239 | April 2014 | April 30, 2020 | April 30, 2020 | March 18, 2014 | May 13, 2020 | University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States | https://ClinicalTrials.gov/show/NCT02090582 | |||
| 56 | 56 | NCT04383977 | Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer | Not yet recruiting | No Results Available | Ovarian Cancer | Drug: Apatinib and Etoposide capsule|Drug: Apatinib | Objective response rate (ORR) by investigator|AEs+SAEs|PFS by investigator|Overall Survival (OS)|Pharmacokinetic characteristic | Jiangsu HengRui Medicine Co., Ltd. | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 54 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | Ahead-OC-203 | May 2020 | December 2020 | June 2021 | May 12, 2020 | May 12, 2020 | https://ClinicalTrials.gov/show/NCT04383977 | ||||
| 57 | 57 | NCT02440425 | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | Active, not recruiting | Has Results | Ovarian Cancer | Drug: Pembrolizumab|Drug: Paclitaxel | Progression-free Survival (PFS) at 6 Months|Occurrence of Adverse Events|Response Rate (RR)|Disease Control Rate (DCR)|Duration of Response (DOR)|Median Overall Survival (OS) | H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme Corp. | All | 18 Years and older (Adult, Older Adult) | Phase 2 | 42 | Other|Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | MCC-18207 | October 20, 2015 | April 2020 | September 2023 | May 12, 2015 | June 3, 2021 | November 17, 2021 | H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Duke University, Durham, North Carolina, United States|VCU Massey Cancer Center, Richmond, Virginia, United States | "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02440425/Prot_SAP_000.pdf | https://ClinicalTrials.gov/show/NCT02440425 | |
| 58 | 58 | NCT01196741 | Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer | SaPPrOC | Completed | Has Results | Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer | Drug: Paclitaxel|Drug: Saracatinib|Drug: Matched placebo | 6 Month Progression-free Survival Rate (PFS) (Based on Combined Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 +/- Gynecologic Cancer Intergroup (GCIG) CA125 Criteria)|Overall Survival|Objective Response Rate Based on Investigator Assessment Based on RECIST v1.1 +/- GCIG CA125 Criteria|Median Duration of Response|Quality of Life: Trial Outcome Index (TOI) Based on FACT-O|Median Time To Progression Based on RECIST v1.1 and GCIG CA125 Criteria|Median PFS | University College, London|AstraZeneca|Cancer Research UK | Female | 18 Years and older (Adult, Older Adult) | Phase 2|Phase 3 | 107 | Other|Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment | UCL/09/105|Funder reference (academic)|Funder reference (industry)|2009-017171-13 | March 2011 | November 2012 | January 2014 | September 8, 2010 | May 5, 2015 | May 5, 2015 | Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom|St Bartholomew's Hospital, London, Greater London, United Kingdom|University College London Hospital, London, Greater London, United Kingdom|Guy's Hospital, London, Greater London, United Kingdom|The Royal Mardsen Hospital, London, Greater London, United Kingdom|The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom|Mount Vernon Hospital, Rickmansworth, Middlesex, United Kingdom|The Churchill Hospital, Oxford, Oxfordshire, United Kingdom|Queen's Hospital, Burton upon Trent, Staffordshire, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|St James's University Hospital, Leeds, Yorkshire, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom | https://ClinicalTrials.gov/show/NCT01196741 | |
| 59 | 59 | NCT04516447 | A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer | Recruiting | No Results Available | Solid Tumor|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer | Drug: ZN-c3|Drug: Carboplatin|Drug: Pegylated liposomal doxorubicin|Drug: Paclitaxel|Drug: Gemcitabine | To investigate the safety and tolerability of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine|To identify the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine|To obtain estimates of clinical activity by determining the objective response rate (ORR) of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine|To obtain estimates of clinical activity by determining the duration of response (DOR) of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine|To obtain estimates of clinical activity by determining the progression-free survival (PFS) of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine|To obtain estimates of clinical activity by determining the time to CA125 progression of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine|To investigate the plasma pharmacokinetics (PK) of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine | K-Group Beta | All | 18 Years and older (Adult, Older Adult) | Phase 1 | 140 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | ZN-c3-002 | October 26, 2020 | October 1, 2022 | January 1, 2023 | August 18, 2020 | December 9, 2021 | Site 0103, Houston, Texas, United States|Site 2707, South Brisbane, Queensland, Australia|Site 2708, Sunshine Coast, Queensland, Australia|Site 2706, Melbourne, Victoria, Australia|Site 2705, Nedlands, Western Australia, Australia|Site 1001, Banja Luka, Bosnia and Herzegovina|Site 1002, Sarajevo, Bosnia and Herzegovina|Site 1003, Tuzla, Bosnia and Herzegovina|Site 1202, Panagyurishte, Bulgaria|Site 1201, Sofia, Bulgaria|Site 1401, Tbilisi, Georgia|Site 2903, Seoul, Korea, Republic of|Site 2904, Seoul, Korea, Republic of|Site 1902, Belgrade, Serbia | https://ClinicalTrials.gov/show/NCT04516447 | |||
| 60 | 60 | NCT05107739 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | Not yet recruiting | No Results Available | Platinum-resistant Ovarian Cancer|Endometrial Cancer|Cervical Cancer | Biological: Drug Product De-TIL-0255 | Incidence of treatment emergent adverse events|Incidence of all deaths|Incidence of dose limiting toxicities|Objective response rate (ORR) per disease-specific response criteria as assessed by the Investigator|Duration of response (DOR) as assessed by the Investigator|Disease control rate (DCR) as assessed by the Investigator|Progression-free survival (PFS) as assessed by the Investigator|Overall survival (OS) as assessed by the Investigator|Changes from baseline in immune cell infiltration in the tumor following DeTIL-0255 infusion | Nurix Therapeutics, Inc. | Female | 18 Years to 70 Years (Adult, Older Adult) | Phase 1 | 50 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | NX-DeTIL-0255-201 | November 2021 | December 2025 | July 2026 | November 4, 2021 | November 4, 2021 | https://ClinicalTrials.gov/show/NCT05107739 | ||||
| 61 | 61 | NCT05043402 | A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer | Not yet recruiting | No Results Available | Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma | Drug: navicixizumab|Device: Xerna™ TME Panel | ORR|PFS|OS|TTR|DCR|DOR | OncXerna Theraputics, Inc. | Female | 18 Years and older (Adult, Older Adult) | Phase 3 | 400 | Industry | Interventional | Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | ONCX-NAV-G301|2021-001933-38 | November 1, 2021 | November 15, 2023 | August 15, 2024 | September 14, 2021 | September 20, 2021 | https://ClinicalTrials.gov/show/NCT05043402 | ||||
| 62 | 62 | NCT04000295 | Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer | Recruiting | No Results Available | Ovarian Cancer | Drug: Apatinib|Drug: Etoposide|Drug: Paclitaxel | Progression free survival(PFS) by independent review committee(IRC)|The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)|PFS by investigator|Objective Response Rate (ORR)|Overall Survival (OS)|EQ-5D-5L questionnaire|FOSI-8 questionnaire | Jiangsu HengRui Medicine Co., Ltd. | Female | 18 Years and older (Adult, Older Adult) | Phase 3 | 280 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | Ahead-OC-301 | August 16, 2019 | January 2021 | July 2022 | June 27, 2019 | October 8, 2019 | Sun Yat-sen University, Guangzhou, Guangdong, China | https://ClinicalTrials.gov/show/NCT04000295 | |||
| 63 | 63 | NCT02900560 | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer | Completed | No Results Available | Epithelial Ovarian Cancer | Drug: CC-486|Biological: Pembrolizumab | Number of subjects with grade 3, 4, or 5 adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03|Number of subjects with with irPR, irCR or irSD as assessed by irRECIST|Number of subjects with treatment emergent adverse events as assessed by CTCAE v4.03 | Translational Research in Oncology|Celgene | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 34 | Other|Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | TRIO026 | December 20, 2016 | May 27, 2021 | May 27, 2021 | September 14, 2016 | September 24, 2021 | UCLA, Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States | https://ClinicalTrials.gov/show/NCT02900560 | |||
| 64 | 64 | NCT02963831 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Active, not recruiting | No Results Available | Colorectal Cancer|Platinum-resistant Ovarian Cancer|Appendiceal Cancer | Biological: ONCOS-102|Drug: Durvalumab | Number of Adverse Events|Clinical Benefit (Complete Response, Partial Response and Stable Disease) for Cohorts 1 & 2|Objective Response Rate for Cohorts 1 & 2|Progression-free survival for Cohorts 1 & 2|Overall Survival for Cohorts 1 & 2 | Ludwig Institute for Cancer Research|Cancer Research Institute, New York City|MedImmune LLC|Targovax ASA | All | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 67 | Other|Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | LUD2015-008 | September 7, 2017 | June 2022 | June 2023 | November 15, 2016 | November 16, 2021 | Research Facility, San Diego, California, United States|Research Facility, Miami, Florida, United States|Research Facility, Buffalo, New York, United States|Research Facility, New York, New York, United States|Research Facility, Toledo, Ohio, United States|Research Facility, Charlottesville, Virginia, United States | https://ClinicalTrials.gov/show/NCT02963831 | |||
| 65 | 65 | NCT02659384 | Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer | Active, not recruiting | No Results Available | Ovarian Neoplasms | Drug: Bevacizumab|Drug: atezolizumab|Drug: acetylsalicylic acid|Drug: placebo | Progression free survival (PFS) at 6 months assessed by Response Evaluation Criteria in Solid Tumors (RECIST) | European Organisation for Research and Treatment of Cancer - EORTC | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 122 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment | EORTC-1508|2015-004601-17 | December 2016 | February 2021 | February 2023 | January 20, 2016 | July 31, 2020 | Assistance Publique - Hopitaux de Paris - Hopital Europeen Georges Pompidou, Paris, France|Centre Hospitalier Privé Saint-Grégoire, Saint-Grégoire, France|Academisch Medisch Centrum - Universiteit van Amsterdam, Amsterdam, Netherlands|Leiden University Medical Centre, Leiden, Netherlands|Radboudumc - Radboud University Medical Center Nijmegen, Nijmegen, Netherlands|Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia), Badalona, Spain|Hospital Universitario San Carlos, Madrid, Spain|Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital, London, United Kingdom|Royal Marsden Hospital - Chelsea, London, London, United Kingdom|Royal Marsden Hospital - Sutton, Surrey, Sutton, United Kingdom | https://ClinicalTrials.gov/show/NCT02659384 | |||
| 66 | 66 | NCT04055038 | Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) | EPITOC | Unknown status | No Results Available | Ovarian Cancer|Ovarian Neoplasms|Serous Adenocarcinoma|BRCA1 Mutation|BRCA2 Mutation|Chemotherapy | Drug: Platinum-Based Drug|Drug: Conventional chemotherapy | Objective response rate (RR) according to RECIST 1.1 criteria|Overall survival defined as time from randomization to death from any reason;|Progression-free survival|Overall survival|Progression-free survival 2 (PFS2) | Blokhin's Russian Cancer Research Center | Female | 18 Years to 70 Years (Adult, Older Adult) | Phase 2|Phase 3 | 164 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | PROC2019 | September 1, 2019 | September 1, 2021 | January 1, 2022 | August 13, 2019 | August 13, 2019 | N.N. Blokhin Cancer Research Center, Moscow, Russian Federation | https://ClinicalTrials.gov/show/NCT04055038 | ||
| 67 | 67 | NCT00403429 | MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | Completed | No Results Available | Ovarian Cancer | Drug: capecitabine | objective response rate|toxicity | National Cancer Institute, Naples | Female | up to 75 Years (Child, Adult, Older Adult) | Phase 2 | 36 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | MITO-6|EudraCT number 2006-001724-40 | March 2006 | January 2008 | July 2008 | November 23, 2006 | January 14, 2016 | Clinica Malzoni, Reparto di Ginecologia Oncologica, Avellino, AV, Italy|Ospedale Regionale Miulli, Divisione Medicina Interna Sezione Oncologica, Acquaviva delle Fonti, BA, Italy|IRCCS Oncologico Bari, Oncologia Medica, Bari, BA, Italy|Ospedale Fatebenefratelli, U.O. di Oncologia, Benevento, BN, Italy|Ospedale Cannizzaro, Divisione di Ostetricia e Ginecologia, Catania, CT, Italy|IRCCS Casa Solllievo della Sofferenza, San Giovanni Rotondo, FG, Italy|Azienda Ospedaliera Carlo Poma, Divisione di Oncologia ed Ematologia, Mantova, MN, Italy|Ospedale Ramazzini, Day Hospital Oncologico, Carpi, MO, Italy|Policlinico Universitario P. Giaccone, Palermo, PA, Italy|Casa di Cura La Maddalena S.p.A., Dipartimento Oncologico, Palermo, PA, Italy|Ospedale S. Massimo, Day Hospital Oncologico, Penne, PE, Italy|Centro di Riferimento Oncologico, Divisione di Oncolgia Medica C, Aviano, PN, Italy|Azienda Ospedaliera S. Maria degli Angeli, Servizio di Oncologia, Pordenone, PN, Italy|Ospedale S. Bortolo ULSS 6, U.O. di Oncologia Medica, Vicenza, VI, Italy|Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B, Napoli, Italy|Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C, Napoli, Italy|Ospedale S. Giovanni Calibita Fatebenefratelli, Roma, Italy | https://ClinicalTrials.gov/show/NCT00403429 | |||
| 68 | 68 | NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | Recruiting | No Results Available | Ovarian Cancer|Recurrent Ovarian Carcinoma | Procedure: secondary cytoreductive surgery|Drug: Chemotherapy | progression free survival (PFS)|Overall survival (OS)|Adverse events (AE) | Menoufia University | Female | 18 Years to 70 Years (Adult, Older Adult) | Phase 2|Phase 3 | 30 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 388 | April 1, 2021 | March 30, 2023 | March 30, 2023 | March 12, 2021 | March 12, 2021 | Menoufia University, Faculty of medicine, Shibīn Al Kawm, Menoufia, Egypt | https://ClinicalTrials.gov/show/NCT04795596 | |||
| 69 | 69 | NCT02728622 | Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane | Completed | No Results Available | Ovarian Cancer|Peritoneal Cancer|Cancer of the Fallopian Tube | Drug: Tamoxifen|Drug: Chemotherapy | Quality-adjusted survival|progression-free survival|overall survival | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Female | 18 Years and older (Adult, Older Adult) | Phase 3 | 241 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | NSGO-OC-0101 | March 2002 | January 2008 | January 2009 | April 5, 2016 | April 5, 2016 | https://ClinicalTrials.gov/show/NCT02728622 | ||||
| 70 | 70 | NCT02839707 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | No Results Available | High Grade Fallopian Tube Serous Adenocarcinoma|High Grade Ovarian Serous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Fallopian Tube Clear Cell Adenocarcinoma|Recurrent Fallopian Tube Endometrioid Adenocarcinoma|Recurrent Fallopian Tube Undifferentiated Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Ovarian Clear Cell Adenocarcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Ovarian Undifferentiated Carcinoma|Recurrent Platinum-Resistant Fallopian Tube Carcinoma|Recurrent Platinum-Resistant Ovarian Carcinoma|Recurrent Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Clear Cell Adenocarcinoma|Recurrent Primary Peritoneal Endometrioid Adenocarcinoma|Recurrent Primary Peritoneal Undifferentiated Carcinoma | Drug: Atezolizumab|Biological: Bevacizumab|Drug: Pegylated Liposomal Doxorubicin Hydrochloride|Other: Quality-of-Life Assessment | Incidence of dose limiting toxicities (DLT) of experimental regimens|Progression free survival (PFS) (Phase II)|PFS (Phase III)|Overall survival (OS) (Phase III)|Objective response rate (ORR) (partial or complete response) (Phase II)|ORR (partial or complete response) (Phase III)|Frequency and severity of adverse events (Phase II)|Frequency and severity of adverse events (Phase III)|Disease-related symptoms (Phase II)|Disease-related symptoms (Phase III)|Patient reported outcomes (PRO) (Phase II)|Patient reported outcomes (Phase III)|PD-L1 expression | National Cancer Institute (NCI)|NRG Oncology | Female | 18 Years and older (Adult, Older Adult) | Phase 2|Phase 3 | 444 | NIH|Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | NCI-2016-01081|NRG-GY009|U10CA180868 | May 12, 2017 | June 30, 2023 | June 30, 2023 | July 21, 2016 | January 28, 2022 | Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|CTCA at Western Regional Medical Center, Goodyear, Arizona, United States|Kingman Regional Medical Center, Kingman, Arizona, United States|Cancer Center at Saint Joseph's, Phoenix, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States|PCR Oncology, Arroyo Grande, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Mercy San Juan Medical Center, Carmichael, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Community Cancer Institute, Clovis, California, United States|University Oncology Associates, Clovis, California, United States|John Muir Medical Center-Concord Campus, Concord, California, United States|Sutter Davis Hospital, Davis, California, United States|Epic Care-Dublin, Dublin, California, United States|Kaiser Permanente Dublin, Dublin, California, United States|Mercy Cancer Center - Elk Grove, Elk Grove, California, United States|Bay Area Breast Surgeons Inc, Emeryville, California, United States|Epic Care Partners in Cancer Care, Emeryville, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Palo Alto Medical Foundation-Fremont, Fremont, California, United States|Fresno Cancer Center, Fresno, California, United States|Kaiser Permanente-Fresno, Fresno, California, United States|Marin Cancer Care Inc, Greenbrae, California, United States|Marin General Hospital, Greenbrae, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente West Los Angeles, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-Ontario, Ontario, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, United States|Eisenhower Medical Center, Rancho Mirage, California, United States|Kaiser Permanente- Marshall Medical Offices, Redwood City, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Mercy Cancer Center - Rocklin, Rocklin, California, United States|Rohnert Park Cancer Center, Rohnert Park, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, United States|Kaiser Permanente Downtown Commons, Sacramento, California, United States|Mercy Cancer Center - Sacramento, Sacramento, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|South Sacramento Cancer Center, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Pacific Central Coast Health Center-San Luis Obispo, San Luis Obispo, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser San Rafael-Gallinas, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Mission Hope Medical Oncology - Santa Maria, Santa Maria, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Northbay Cancer Center, Vacaville, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Epic Care Cyberknife Center, Walnut Creek, California, United States|John Muir Medical Center-Walnut Creek, Walnut Creek, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|Woodland Memorial Hospital, Woodland, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Boulder Community Foothills Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Rocky Mountain Cancer Centers - Centennial, Centennial, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Saint Francis Cancer Center, Colorado Springs, Colorado, United States|Cancer Center of Colorado at Sloan's Lake, Denver, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|Kaiser Permanente-Franklin, Denver, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|The Women's Imaging Center, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Western Surgical Care, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States|Rocky Mountain Cancer Centers - Swedish, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|The Melanoma and Skin Cancer Institute, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States|Kaiser Permanente-Rock Creek, Lafayette, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Kaiser Permanente-Lone Tree, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|National Jewish Health-Northern Hematology Oncology, Thornton, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Danbury Hospital, Danbury, Connecticut, United States|Hartford Hospital, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Beebe South Coastal Health Campus, Frankford, Delaware, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|TidalHealth Nanticoke / Allen Cancer Center, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Kaiser Permanente-Capitol Hill Medical Center, Washington, District of Columbia, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|Northeast Georgia Medical Center Braselton, Braselton, Georgia, United States|Northside Hospital-Forsyth, Cumming, Georgia, United States|Dekalb Medical Center, Decatur, Georgia, United States|Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, United States|CTCA at Southeastern Regional Medical Center, Newnan, Georgia, United States|Low Country Cancer Care, Savannah, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Summit Cancer Care-Memorial, Savannah, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Summit Cancer Care-Candler, Savannah, Georgia, United States|Hawaii Cancer Care - Savio, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Queen's Cancer Center - Pearlridge, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii, United States|Island Urology, Honolulu, Hawaii, United States|Queen's Cancer Cenrer - POB I, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|Queen's Cancer Center - Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Saint Anthony's Health, Alton, Illinois, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Illinois CancerCare-Dixon, Dixon, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Sudarshan K Sharma MD Limited-Gynecologic Oncology, Hinsdale, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Marjorie Weinberg Cancer Center at Loyola-Gottlieb, Melrose Park, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|North Shore Medical Center, Skokie, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Illinois CancerCare - Washington, Washington, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Parkview Regional Medical Center, Fort Wayne, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Franciscan Saint Elizabeth Health - Lafayette East, Lafayette, Indiana, United States|Woodland Cancer Care Center, Michigan City, Indiana, United States|Franciscan Health Mooresville, Mooresville, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Union Hospital, Terre Haute, Indiana, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Coffeyville Regional Medical Center, Coffeyville, Kansas, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|HaysMed University of Kansas Health System, Hays, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Olathe Health Cancer Center, Olathe, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States|Ascension Via Christi - Pittsburg, Pittsburg, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka, Kansas, United States|University of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Baptist Health Corbin, Corbin, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Elizabeth Medical Center South, Edgewood, Kentucky, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Norton Hospital Pavilion and Medical Campus, Louisville, Kentucky, United States|Baptist Health Louisville, Louisville, Kentucky, United States|Norton Suburban Hospital and Medical Campus, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Norton Brownsboro Hospital and Medical Campus, Louisville, Kentucky, United States|UofL Health Medical Center Northeast, Louisville, Kentucky, United States|Baptist Health Madisonville/Merle Mahr Cancer Center, Madisonville, Kentucky, United States|Baptist Health Paducah, Paducah, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States|Hematology/Oncology Clinic PLLC, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Medical Center of Baton Rouge, Baton Rouge, Louisiana, United States|Ochsner High Grove, Baton Rouge, Louisiana, United States|Women's Cancer Care-Covington, Covington, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Baptist Medical Center, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Kaiser Permanente-Woodlawn Medical Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|University of Maryland Shore Medical Center at Easton, Easton, Maryland, United States|Kaiser Permanente-Gaithersburg Medical Center, Gaithersburg, Maryland, United States|Kaiser Permanente - Kensington Medical Center, Kensington, Maryland, United States|Kaiser Permanente - Largo Medical Center, Largo, Maryland, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Lahey Medical Center-Peabody, Peabody, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Winchester Hospital, Winchester, Massachusetts, United States|UMass Memorial Medical Center - Memorial Division, Worcester, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|Henry Ford Cancer Institute-Downriver, Brownstown, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Henry Ford Medical Center-Fairlane, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Ascension Borgess Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|Cancer and Hematology Centers of Western Michigan - Norton Shores, Norton Shores, Michigan, United States|Henry Ford Medical Center-Columbus, Novi, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Huron Medical Center PC, Port Huron, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Henry Ford Macomb Health Center - Shelby Township, Shelby, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Minnesota Oncology - Burnsville, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Sanford Thief River Falls Medical Center, Thief River Falls, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Sanford Cancer Center Worthington, Worthington, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Parkland Health Center - Farmington, Farmington, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Truman Medical Centers, Kansas City, Missouri, United States|University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Las Vegas Urology - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pebble, Henderson, Nevada, United States|Urology Specialists of Nevada - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pecos, Las Vegas, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|OptumCare Cancer Care at Charleston, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Las Vegas Prostate Cancer Center, Las Vegas, Nevada, United States|Las Vegas Urology - Sunset, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Southwest, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|Cancer Therapy and Integrative Medicine, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Las Vegas Urology - Cathedral Rock, Las Vegas, Nevada, United States|Las Vegas Urology - Smoke Ranch, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Northwest, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|AtlantiCare Health Park-Cape May Court House, Cape May Court House, New Jersey, United States|AtlantiCare Surgery Center, Egg Harbor Township, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The Cancer Institute of New Jersey Hamilton, Hamilton, New Jersey, United States|Monmouth Medical Center Southern Campus, Lakewood, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The Valley Hospital-Luckow Pavilion, Paramus, New Jersey, United States|Neurosurgeons of New Jersey-Ridgewood, Ridgewood, New Jersey, United States|Valley Hospital, Ridgewood, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States|Valley Medical Group - Wayne Multispecialty Practice, Wayne, New Jersey, United States|Valley Health System-Hematology/Oncology, Westwood, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, United States|Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States|Women's Cancer Care Associates LLC, Albany, New York, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States|Mount Sinai Chelsea, New York, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Lenox Hill Hospital, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|Manhattan Eye Ear and Throat Hospital, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|SUNY Upstate Medical Center-Community Campus, Syracuse, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Dickstein Cancer Treatment Center, White Plains, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|Hope Women's Cancer Centers-Asheville, Asheville, North Carolina, United States|Cone Health Cancer Center at Alamance Regional, Burlington, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Atrium Health Cabarrus/LCI-Concord, Concord, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Novant Health Presbyterian Medical Center Huntersville, Huntersville, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Novant Health Cancer Institute - Kernersville, Kernersville, North Carolina, United States|Cone Heath Cancer Center at Mebane, Mebane, North Carolina, United States|Novant Health Cancer Institute - Mount Airy, Mount Airy, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States|Annie Penn Memorial Hospital, Reidsville, North Carolina, United States|Novant Health Cancer Institute - Statesville, Statesville, North Carolina, United States|Novant Health Cancer Institute - Thomasville, Thomasville, North Carolina, United States|Novant Health Cancer Institute - Wilkesboro, Wilkesboro, North Carolina, United States|New Hanover Regional Medical Center/Zimmer Cancer Center, Wilmington, North Carolina, United States|Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford South University Medical Center, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Aultman Alliance Community Hospital, Alliance, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Saint Elizabeth Boardman Hospital, Boardman, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Mount Carmel Grove City Hospital, Grove City, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Saint Rita's Medical Center, Lima, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio, United States|UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Mercy Health Perrysburg Cancer Center, Perrysburg, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|Mercy Health - Saint Anne Hospital, Toledo, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|University Hospitals Sharon Health Center, Wadsworth, Ohio, United States|Saint Joseph Warren Hospital, Warren, Ohio, United States|University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|Saint Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Cancer Treatment Centers of America, Tulsa, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Jefferson Abington Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Saint Luke's University Hospital-Bethlehem Campus, Bethlehem, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Chambersburg Hospital, Chambersburg, Pennsylvania, United States|Main Line Health Center-Collegeville, Collegeville, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Ephrata Cancer Center, Ephrata, Pennsylvania, United States|Main Line Health Center-Exton, Exton, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|Cherry Tree Cancer Center, Hanover, Pennsylvania, United States|UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Jefferson Hospital, Jefferson Hills, Pennsylvania, United States|Lancaster General Ann B Barshinger Cancer Institute, Lancaster, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Sechler Family Cancer Center, Lebanon, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Riddle Memorial Hospital, Media, Pennsylvania, United States|Forbes Hospital, Monroeville, Pennsylvania, United States|Medical Center Clinic-New Castle Office, New Castle, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Chester County Hospital, West Chester, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Wexford Health and Wellness Pavilion, Wexford, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|WellSpan Health-York Cancer Center, York, Pennsylvania, United States|WellSpan Health-York Hospital, York, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|MGC Hematology Oncology-Union, Union, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Bristol Regional Medical Center, Bristol, Tennessee, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Vanderbilt-Ingram Cancer Center Cool Springs, Franklin, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Wellmont Medical Associates Oncology and Hematology-Johnson City, Johnson City, Tennessee, United States|Regional Cancer Center at Indian Path Community Hospital, Kingsport, Tennessee, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Thompson Cancer Survival Center - West, Knoxville, Tennessee, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Thompson Oncology Group-Oak Ridge, Oak Ridge, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Methodist Willowbrook Hospital, Houston, Texas, United States|Houston Methodist West Hospital, Houston, Texas, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States|Houston Methodist The Woodlands Hospital, The Woodlands, Texas, United States|Wellmont Medical Associates-Bristol, Bristol, Virginia, United States|Kaiser Permanente-Burke Medical Center, Burke, Virginia, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Kaiser Permanente Tysons Corner Medical Center, McLean, Virginia, United States|Southwest VA Regional Cancer Center, Norton, Virginia, United States|Virginia Gynecologic Oncology, Richmond, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Carilion Clinic Gynecological Oncology, Roanoke, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|MultiCare Auburn Medical Center, Auburn, Washington, United States|Virginia Mason Bainbridge Island Medical Center, Bainbridge Island, Washington, United States|Overlake Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Virginia Mason Federal Way Medical Center, Federal Way, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Gig Harbor, Gig Harbor, Washington, United States|MultiCare Gig Harbor Medical Park, Gig Harbor, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Northwest Cancer Clinic, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Virginia Mason Lynnwood Medical Center, Lynnwood, Washington, United States|Jefferson Healthcare, Port Townsend, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Peninsula Cancer Center, Poulsbo, Washington, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Puyallup, Puyallup, Washington, United States|Valley Medical Center, Renton, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|University of Washington Medical Center - Montlake, Seattle, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|MultiCare Deaconess Cancer and Blood Specialty Center - Valley, Spokane Valley, Washington, United States|MultiCare Deaconess Cancer and Blood Specialty Center - Downtown, Spokane, Washington, United States|MultiCare Deaconess Cancer and Blood Specialty Center - North, Spokane, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Jackson Hall, Tacoma, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Saint Joe's, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|United Hospital Center, Bridgeport, West Virginia, United States|West Virginia University Charleston Division, Charleston, West Virginia, United States|WVUH-Berkely Medical Center, Martinsburg, West Virginia, United States|Monongalia Hospital, Morgantown, West Virginia, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Camden Clark Medical Center, Parkersburg, West Virginia, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Aurora Health Center-Fond du Lac, Fond Du Lac, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Mercyhealth Hospital and Cancer Center - Janesville, Janesville, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Marshfield Medical Center - Weston, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Advance Oncology Center, Aguadilla, Puerto Rico|Doctor's Cancer Center-Arecibo, Arecibo, Puerto Rico|Cancer Center-Metro Medical Center Bayamon, Bayamon, Puerto Rico|Hematologia Oncologia San Pablo, Bayamon, Puerto Rico|HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico|Doctors Cancer Center, Manati, Puerto Rico|Instituto Oncologia Moderna Ponce, Ponce, Puerto Rico|San Juan Community Oncology Group, San Juan, Puerto Rico|Primary Care Physician Group, San Juan, Puerto Rico|Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico|San Juan City Hospital, San Juan, Puerto Rico|Centro de Hematologia y Oncologia del Sur, Santa Isabel, Puerto Rico | https://ClinicalTrials.gov/show/NCT02839707 | |||
| 71 | 71 | NCT00813254 | Cost Utility Analysis in Recurrent Ovarian Cancer | Withdrawn | No Results Available | Ovarian Cancer | Behavioral: Questionnaire | Mean Score for the FACT-O instrument | M.D. Anderson Cancer Center | Female | Child, Adult, Older Adult | 0 | Other | Observational | Observational Model: Cohort|Time Perspective: Retrospective | 2007-0611 | December 2008 | January 2011 | January 2011 | December 23, 2008 | April 19, 2012 | UT MD Anderson Cancer Center, Houston, Texas, United States | https://ClinicalTrials.gov/show/NCT00813254 | ||||
| 72 | 72 | NCT00003449 | Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer | Completed | No Results Available | Ovarian Cancer | Drug: dexamethasone|Drug: gemcitabine hydrochloride|Drug: paclitaxel | University of Southern California|National Cancer Institute (NCI) | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 35 | Other|NIH | Interventional | Primary Purpose: Treatment | CDR0000066478 (5O-98-1)|LAC-USC-5O981|NCI-G98-1460 | May 1998 | June 2002 | February 2004 | September 24, 2003 | May 22, 2014 | USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States | https://ClinicalTrials.gov/show/NCT00003449 | ||||
| 73 | 73 | NCT00976911 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | Completed | Has Results | Ovarian Cancer | Drug: bevacizumab [Avastin]|Drug: liposomal doxorubicin|Drug: paclitaxel|Drug: topotecan | Percentage of Participants With Disease Progression or Death (Data Cutoff 14 November 2011)|Progression Free Survival (PFS; Data Cutoff 14 November 2011)|Percentage of Participants With Best Overall Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) Per Modified RECIST (Data Cutoff 14 November 2011)|Duration of Objective Response (Data Cutoff 14 November 2011)|Percentage of Participants Who Died (Data Cutoff 25 January 2013)|Overall Survival (Data Cutoff 25 January 2013)|European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Ovarian (OV) 28 Abdominal/Gastrointestinal (AB/GI) Symptom Scale - Percentage of Responders (Data Cutoff 14 November 2011) | Hoffmann-La Roche | Female | 18 Years and older (Adult, Older Adult) | Phase 3 | 361 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | MO22224|2009-011400-33 | October 2009 | July 2014 | July 2014 | September 15, 2009 | February 25, 2015 | February 25, 2015 | Bruxelles, Belgium|Edegem, Belgium|Leuven, Belgium|Namur, Belgium|Banja Luka, Bosnia and Herzegovina|Sarajevo, Bosnia and Herzegovina|Tuzla, Bosnia and Herzegovina|Herlev, Denmark|Herning, Denmark|København, Denmark|Odense, Denmark|Kuopio, Finland|Oulu, Finland|Avignon, France|Bordeaux, France|Bordeaux, France|Bordeaux, France|Brive La Gaillarde, France|Caen, France|Clermont Ferrand, France|Colmar, France|Grenoble, France|La Roche Sur Yon, France|La Source, France|Le Chesnay, France|Le Mans, France|Lille, France|Lyon, France|Metz Tessy, France|Mont-de-marsan, France|Montpellier, France|Mougins, France|Nancy, France|Nantes, France|Nice, France|Nimes, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Perigueux, France|Reims CEDEX, France|Rouen, France|Saint Brieuc, France|Saint Herblain, France|Saint Nazaire, France|St Cloud, France|Strasbourg, France|Thonon Les Bains, France|Toulouse, France|Vandoeuvre Les Nancy, France|Berlin, Germany|Berlin, Germany|Düsseldorf, Germany|Düsseldorf, Germany|Erlangen, Germany|Essen, Germany|Essen, Germany|Frankfurt, Germany|Hamburg, Germany|Hannover, Germany|Hildesheim, Germany|Kassel, Germany|Kiel, Germany|Krefeld, Germany|Lübeck, Germany|Mannheim, Germany|Muenchen, Germany|Nuernberg, Germany|Offenbach, Germany|Recklinghausen, Germany|Rostock, Germany|Solingen, Germany|Stuttgart, Germany|Tübingen, Germany|Ulm, Germany|Wiesbaden, Germany|Athens, Greece|Aviano, Friuli-Venezia Giulia, Italy|Udine, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Bergamo, Lombardia, Italy|Mantova, Lombardia, Italy|Milano, Lombardia, Italy|Amersfoort, Netherlands|Den Haag, Netherlands|Eindhoven, Netherlands|Groningen, Netherlands|Nieuwegein, Netherlands|Utrecht, Netherlands|Oslo, Norway|Trondheim, Norway|Lisboa, Portugal|Porto, Portugal|Sabadell, Barcelona, Barcelona, Spain|Santander, Cantabria, Spain|Palma de Mallorca, Islas Baleares, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Cordoba, Spain|Lerida, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Murcia, Spain|Valencia, Spain|Valencia, Spain|Zaragoza, Spain|Linkoeping, Sweden|Umea, Sweden|Uppsala, Sweden|Örebro, Sweden|Adana, Turkey|Ankara, Turkey|Istanbul, Turkey|Istanbul, Turkey|Kocaeli, Turkey | https://ClinicalTrials.gov/show/NCT00976911 | ||
| 74 | 74 | NCT04608409 | Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer | Recruiting | No Results Available | Ovarian Cancer | Drug: Lapatinib and Paclitaxel | Progression-free survival.|Dose-limiting toxicity|Change in plasma concentration of lapatinib. | Frederick R. Ueland, M.D.|University of Kentucky | Female | 18 Years to 100 Years (Adult, Older Adult) | Phase 1 | 15 | Other | Interventional | Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | MCC-20-GYN-06 | November 16, 2020 | June 30, 2025 | June 30, 2025 | October 29, 2020 | December 8, 2021 | Markey Cancer Center, Lexington, Kentucky, United States | https://ClinicalTrials.gov/show/NCT04608409 | |||
| 75 | 75 | NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | Terminated | Has Results | Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer | Drug: Ganetespib|Drug: Paclitaxel | Progression Free Survival (PFS) | Medical University Innsbruck|European Commission | Female | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 133 | Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | GANNET53|2013-003868-31 | July 4, 2014 | November 30, 2017 | December 4, 2017 | December 16, 2013 | August 13, 2019 | August 13, 2019 | Medical University Innsbruck, Department for Gynaecology and Obstetrics, Innsbruck, Austria|Katholieke Universiteit Leuven, Dept. of Gynaecologic Oncology, Leuven, Belgium|Centre de lutte contre le cancer Francois Baclesse, Caen, France|Centre Anticancereux Léon Bérard, Lyon, France|Assistance Publique - Hôpitaux de Paris Medical Oncology Department, Paris, France|Universitätsmedizin Berlin Charité, Dept. for Gynecology, Berlin, Germany|University Hospital Carl Gustav Carus Dresden, Department of Gynaecology and Obstetrics, Dresden, Germany|Kliniken Essen Mitte, Evang. Huyssens-Stiftung / Knappschaft GmbH Department of Gynaecologic Oncology, Essen, Germany|Universitätsklinikum Hamburg-Eppendorf Dept. of Gynecology and Gynecologic Oncology, Hamburg, Germany|Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany | "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02012192/Prot_SAP_000.pdf | https://ClinicalTrials.gov/show/NCT02012192 | |
| 76 | 76 | NCT02195973 | Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer | Completed | No Results Available | Recurrent Ovarian Cancer | Drug: LDE225 | Safety of weekly paclitaxel + LDE225 treatment|Assessment of toxicities|Optimal dose of LDE225 with paclitaxel | University of Alabama at Birmingham|Novartis Pharmaceuticals | Female | 19 Years and older (Adult, Older Adult) | Phase 1 | 15 | Other|Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | F140214007 (UAB 1357)|000505867 | September 2014 | December 10, 2016 | September 30, 2017 | July 21, 2014 | June 18, 2018 | University of Alabama at Birmingham, Birmingham, Alabama, United States | https://ClinicalTrials.gov/show/NCT02195973 | |||
| 77 | 77 | NCT02502266 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | Recruiting | No Results Available | Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma | Drug: Cediranib|Drug: Cediranib Maleate|Drug: Olaparib|Drug: Paclitaxel|Drug: Pegylated Liposomal Doxorubicin Hydrochloride|Other: Questionnaire Administration|Drug: Topotecan|Drug: Topotecan Hydrochloride | Progression-free survival (PFS) (Phase II and Phase III)|Overall survival (OS) (Phase III)|Objective response rate (partial or complete response) (Phase II and Phase III)|Incidence of adverse events (Phase II and Phase III) | National Cancer Institute (NCI)|Canadian Cancer Trials Group|NRG Oncology | Female | 18 Years and older (Adult, Older Adult) | Phase 2|Phase 3 | 562 | NIH|Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | NCI-2015-00651|NRG-GY005|s16-01681|U10CA180868 | February 5, 2016 | June 30, 2023 | June 30, 2023 | July 20, 2015 | January 24, 2022 | University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Mercy San Juan Medical Center, Carmichael, California, United States|Mercy Cancer Center - Elk Grove, Elk Grove, California, United States|Marin Cancer Care Inc, Greenbrae, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Mercy Cancer Center - Rocklin, Rocklin, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Kaiser Permanente Downtown Commons, Sacramento, California, United States|Mercy Cancer Center - Sacramento, Sacramento, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Pacific Central Coast Health Center-San Luis Obispo, San Luis Obispo, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Woodland Memorial Hospital, Woodland, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Kaiser Permanente-Franklin, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States|Kaiser Permanente-Rock Creek, Lafayette, Colorado, United States|Kaiser Permanente-Lone Tree, Lone Tree, Colorado, United States|Danbury Hospital, Danbury, Connecticut, United States|Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States|Hartford Hospital, Hartford, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Middlesex Hospital, Middletown, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Orlando Health Cancer Institute, Orlando, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|WellStar Cobb Hospital, Austell, Georgia, United States|WellStar Health System Inc, Marietta, Georgia, United States|Wellstar Kennestone Hospital, Marietta, Georgia, United States|WellStar North Fulton Hospital, Roswell, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|WellStar Vinings Health Park, Smyrna, Georgia, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Presence Saint Joseph Hospital-Chicago, Chicago, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Sudarshan K Sharma MD Limited-Gynecologic Oncology, Hinsdale, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Parkview Regional Medical Center, Fort Wayne, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Associates In Womens Health, Wichita, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Saint Elizabeth Medical Center South, Edgewood, Kentucky, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Hematology/Oncology Clinic PLLC, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Woman's Hospital, Baton Rouge, Louisiana, United States|Women's Cancer Care-Covington, Covington, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|UM Upper Chesapeake Medical Center, Bel Air, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|TidalHealth Richard A Henson Cancer Institute, Ocean Pines, Maryland, United States|TidalHealth Peninsula Regional, Salisbury, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|UMass Memorial Medical Center - Memorial Division, Worcester, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Cancer Institute-Downriver, Brownstown, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The Cancer Institute of New Jersey Hamilton, Hamilton, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Jersey Shore Medical Center, Neptune, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|MD Anderson Cancer Center at Cooper-Voorhees, Voorhees, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, United States|Women's Cancer Care Associates LLC, Albany, New York, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|State University of New York Downstate Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Dickstein Cancer Treatment Center, White Plains, New York, United States|AdventHealth Infusion Center Asheville, Asheville, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|AdventHealth Infusion Center Haywood, Clyde, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|AdventHealth Hendersonville, Hendersonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States|New Hanover Regional Medical Center/Zimmer Cancer Center, Wilmington, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States|Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Cancer Treatment Centers of America, Tulsa, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Charles Health System, Bend, Oregon, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Jefferson Abington Hospital, Abington, Pennsylvania, United States|Saint Luke's University Hospital-Bethlehem Campus, Bethlehem, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Ephrata Cancer Center, Ephrata, Pennsylvania, United States|Ephrata Community Hospital, Ephrata, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|Cherry Tree Cancer Center, Hanover, Pennsylvania, United States|UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg, Pennsylvania, United States|Sechler Family Cancer Center, Lebanon, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group PC-Robert Packer Hospital, Sayre, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Wexford Health and Wellness Pavilion, Wexford, Pennsylvania, United States|UPMC Susquehanna, Williamsport, Pennsylvania, United States|Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|WellSpan Health-York Hospital, York, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|South Carolina Cancer Specialists PC, Hilton Head Island, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|MGC Hematology Oncology-Union, Union, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Regional Cancer Center at Indian Path Community Hospital, Kingsport, Tennessee, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Thompson Cancer Survival Center - West, Knoxville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Methodist Willowbrook Hospital, Houston, Texas, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|South Jordan Health Center, South Jordan, Utah, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|VCU Massey Cancer Center at Stony Point, Richmond, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Skagit Valley Hospital Regional Cancer Care Center, Mount Vernon, Washington, United States|Skagit Valley Hospital, Mount Vernon, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|University of Washington Medical Center - Northwest, Seattle, Washington, United States|Women's Cancer Center of Seattle, Seattle, Washington, United States|University of Washington Medical Center - Montlake, Seattle, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|West Virginia University Charleston Division, Charleston, West Virginia, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States|Monongalia Hospital, Morgantown, West Virginia, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Ascension Saint Elizabeth Hospital, Appleton, Wisconsin, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Aurora Health Center-Fond du Lac, Fond Du Lac, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Marinette, Marinette, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Ascension Columbia Saint Mary's Hospital Ozaukee, Mequon, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Ascension Columbia Saint Mary's Hospital - Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|Ascension Mercy Hospital, Oshkosh, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Ascension Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Marshfield Medical Center - Weston, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Algoma District Cancer Program Sault Area Hospital, Sault Ste Marie, Ontario, Canada|Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada|CIUSSSEMTL-Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), Quebec City, Quebec, Canada|Ehime University Hospital, Toon, Ehime, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kagoshima City Hospital, Kagoshima City, Kagoshima, Japan|The Cancer Institute Hospital Of JFCR, Koto-ku, Tokyo, Japan|Kindai University, Osaka, Japan|Saitama Medical University International Medical Center, Saitama, Japan|National Cancer Center Hospital, Tokyo, Japan|Keimyung University-Dongsan Medical Center, Dalseo-gu, Daegu, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam City, Kyeonggi-do, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Korea, Republic of|Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico | https://ClinicalTrials.gov/show/NCT02502266 | |||
| 78 | 78 | NCT01608009 | [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer | PAZPET-1 | Completed | No Results Available | Ovarian Neoplasm | Drug: Pazopanib and paclitaxel | Assessment of change in [18F]-fluciclatide retention parameters following 1 week of pazopanib treatment|The proportion of women who experience side effects from the combination of paclitaxel and pazopanib|The proportion of patients responding to combination paclitaxel and pazopanib | Imperial College London|GlaxoSmithKline | Female | 18 Years and older (Adult, Older Adult) | Phase 1 | 16 | Other|Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | CRO1627 | July 2012 | May 2015 | April 2016 | May 30, 2012 | March 10, 2017 | Imperial College Healthcare NHS Trust, London, United Kingdom|Southend University Hospital NHS Foundation Trust, Southend, United Kingdom | https://ClinicalTrials.gov/show/NCT01608009 | ||
| 79 | 79 | NCT04502602 | Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer | iNNOVATE | Recruiting | No Results Available | Advanced Solid Tumor|Ovarian Cancer | Drug: Neratinib 160 mg|Drug: Neratinib 200 mg|Drug: Neratinib 240 mg|Drug: Niraparib 100 mg|Drug: Niraparib 200 mg|Drug: Niraparib 300 mg|Drug: Niraparib at RP2D|Drug: Neratinib at RP2D | Phase 1: To determine the Recommended phase 2 dose (RP2D) of niraparib and neratinib in patients with advanced solid tumors|Phase 1b: To evaluate clinical benefit (≥4-month progression-free survival [PFS]) of niraparib and neratinib in patients with platinum-resistant ovarian cancer.|To assess the frequency of adverse events (AEs)|Preliminary efficacy (objective response rate [ORR]) of niraparib and neratinib in patients with advanced solid tumors. | Virginia Commonwealth University|Puma Biotechnology, Inc.|GlaxoSmithKline | All | 18 Years and older (Adult, Older Adult) | Phase 1 | 45 | Other|Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | MCC-18-14152|NCI-2020-05315 | August 24, 2020 | May 31, 2024 | May 31, 2029 | August 6, 2020 | March 2, 2021 | Virginia Commonwealth University, Richmond, Virginia, United States | https://ClinicalTrials.gov/show/NCT04502602 | ||
| 80 | 80 | NCT04389229 | OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial) | OVSTAR | Withdrawn | No Results Available | Ovarian Cancer Metastatic | Drug: cyclophosphamide|Drug: fludarabine|Drug: IL-2 (Proleukin)|Genetic: Unmodified Tumour Infiltrating Lymphocytes (UTIL-01)|Genetic: Gene modified Tumour Infiltrating Lymphocytes (CoTIL-01) | Disease objective response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria|Feasibility of treatment assessed by successful completion of planned treatment|Tolerability and safety assessed according to NCI CTCAE v5.0 grading.|Percentage change in CA125 according to the Gynaecologic Cancer InterGroup CA125 response definition|Feasibility assessed by successful completion of planned treatment.|Progression free survival|Duration of overall response and stable disease|Tolerability and safety assessed according to NCI CTCAE v5.0 grading|Objective response by RECIST v1.1 | Immetacyte Ltd | Female | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 0 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | IMM-2019T-01-OC|2019-000106-30 | July 1, 2020 | March 31, 2023 | July 31, 2025 | May 15, 2020 | December 16, 2020 | Queens Elizabeth Hospital, Birmingham, United Kingdom|The Christies Hospital, Manchester, United Kingdom | https://ClinicalTrials.gov/show/NCT04389229 | ||
| 81 | 81 | NCT00856791 | Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients | Completed | Has Results | Ovarian Cancer | Drug: ON 01910.Na | Progression Free Survival|Number of Adverse Events | Onconova Therapeutics, Inc. | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 1 | Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | Onconova 04-12 | March 2009 | July 2011 | July 2011 | March 6, 2009 | January 8, 2013 | July 21, 2017 | St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States | https://ClinicalTrials.gov/show/NCT00856791 | ||
| 82 | 82 | NCT00428610 | A Study of Chemotherapy Treatment for Patients With Ovarian Cancer | Completed | Has Results | Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer | Drug: LY573636-sodium | Percentage of Participants With Complete Response and Partial Response (Objective Response Rate)|Progression Free Survival|Percentage of Participants With Complete Response, Partial Response, and Stable Disease (Clinical Benefit Rate)|Pharmacokinetics: Maximum Concentration (Cmax) of LY573636|Overall Survival|Duration of Response|Duration of Stable Disease|Number of Participants With Adverse Events (Safety) | Eli Lilly and Company | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 103 | Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 10410|H8K-MC-JZAG | February 2007 | February 2011 | January 2012 | January 30, 2007 | April 19, 2018 | April 19, 2018 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scottsdale, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brescia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation | https://ClinicalTrials.gov/show/NCT00428610 | ||
| 83 | 83 | NCT01175343 | RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Completed | Has Results | Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer | Drug: Gamma-Secretase Inhibitor RO4929097|Other: Laboratory Biomarker Analysis | Four Cycle Progression-free Survival Rate|Overall Response Rate|CA125 Response Rate (GCIG Criteria)|Overall Survival|Frequency and Severity of Adverse Events|Expression of Notch Biomarkers in Advanced Platinum Resistant Ovarian, Fallopian, and Primary Peritoneal Cancers.|Impact of RO49097 on Ascitic Fluid Circulating Tumor Cells | National Cancer Institute (NCI) | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 45 | NIH | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | NCI-2012-03069|PHL-079|8635|N01CM00032|N01CM00038|N01CM00071|N01CM62201|N01CM62203|N01CM62209 | July 2010 | October 2012 | August 2015 | August 4, 2010 | May 24, 2017 | May 24, 2017 | Tower Cancer Research Foundation, Beverly Hills, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Credit Valley Hospital, Mississauga, Ontario, Canada|Ottawa Hospital-Civic Campus, Ottawa, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada | https://ClinicalTrials.gov/show/NCT01175343 | ||
| 84 | 84 | NCT00003297 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer | Completed | No Results Available | Ovarian Cancer | Drug: mitoxantrone hydrochloride|Drug: thiotepa|Drug: topotecan hydrochloride|Procedure: peripheral blood stem cell transplantation | Georgetown University|National Cancer Institute (NCI) | Female | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 50 | Other|NIH | Interventional | Primary Purpose: Treatment | CDR0000066235|P30CA051008|GUMC-97342|NCI-G98-1414 | December 1997 | January 2001 | January 2001 | July 8, 2004 | March 24, 2011 | Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States | https://ClinicalTrials.gov/show/NCT00003297 | ||||
| 85 | 85 | NCT00806156 | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer | Completed | Has Results | Tumor|Ovarian Cancer | Drug: NKTR-102 q14d|Drug: NKTR-102 q21d | Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST): Primary Efficacy Population|Secondary: Best Overall Response by Gynecologic Cancer Intergroup (GCIG) Criteria: MITT Population|Secondary: Best Overall Response by GCIG Criteria: Primary Efficacy Population|Secondary: Best Overall Response by GCIG Criteria: Platinum-Refractory Population|Secondary: Best Overall Response by GCIG Criteria: Prior PLD Therapy Population|Secondary: Kaplan-Meier Estimate of Progression-Free Survival (PFS): MITT Population|Secondary: Kaplan-Meier Estimate of PFS: Primary Efficacy Population|Secondary: Kaplan-Meier Estimate of PFS: Platinum-Refractory Population|Secondary: Kaplan-Meier Estimate of PFS: Prior PLD Therapy Population|Secondary: Kaplan-Meier Analysis of Duration of Overall Response (DoR): MITT Population|Secondary: Kaplan-Meier Analysis of DoR: Primary Efficacy Population|Secondary: Kaplan-Meier Analysis of DoR: Platinum-Refractory Population|Secondary: Kaplan-Meier Analysis of DoR: Prior PLD Therapy Population|Secondary: CA-125 Response Rate: MITT Population|Secondary: CA-125 Response Rate: Primary Efficacy Population|Secondary: CA-125 Response Rate: Platinum-Refractory Population|Secondary: CA-125 Response Rate: Prior PLD Therapy Population|Secondary: Clinical Benefit Rate: MITT Population|Secondary: Clinical Benefit Rate: Primary Efficacy Population|Secondary: Clinical Benefit Rate: Platinum-Refractory Population|Secondary: Clinical Benefit Rate: Prior PLD Therapy Population|Secondary: Kaplan-Meier Analysis of Overall Survival (OS): MITT Population|Secondary: Kaplan-Meier Analysis of OS: Primary Efficacy Population|Secondary: Kaplan-Meier Analysis of OS: Platinum-Refractory Population|Secondary: Kaplan-Meier Analysis of OS: Prior PLD Therapy Population|Secondary: ORR by RECIST: MITT Population|Secondary: ORR by RECIST: Prior PLD Population|Secondary: ORR by RECIST: Platinum-Refractory Population | Nektar Therapeutics | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 178 | Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 08-PIR-04 | October 2008 | October 2012 | January 2013 | December 10, 2008 | June 14, 2021 | July 12, 2021 | Investigator Site - Higland, Highland, California, United States|Investigator Site - Los Angeles, Los Angeles, California, United States|Investigator Site - Newport Beach, Newport Beach, California, United States|Investigator Site - West Palm Beach, West Palm Beach, Florida, United States|Investigator Site - Iowa City, Iowa City, Iowa, United States|Investigator Site - Lansing, Lansing, Michigan, United States|Investigator Site - Winston-Salem, Winston-Salem, North Carolina, United States|Investigator Site - Oklahoma City, Oklahoma City, Oklahoma, United States|Investigator Site - East Providence, East Providence, Rhode Island, United States|Investigator Site - Nashville, Nashville, Tennessee, United States|Investigator Site - Charlottesville, Charlottesville, Virginia, United States|Investigator Site - Gent, Gent, Belgium|Investigator Site - Leuven, Leuven, Belgium|Investigator Site - Liege, Liege, Belgium|Investigator Site - Wilrijk, Wilrijk, Belgium|Investigator Site - Middlesex, Middlesex, Northwood, United Kingdom|Investigator Site - Coventry, Coventry, United Kingdom|Investigator Site - Dundee, Dundee, United Kingdom|Investigator Site - Glasgow, Glasgow, United Kingdom|Investigator Site - Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom | https://ClinicalTrials.gov/show/NCT00806156 | ||
| 86 | 86 | NCT00034151 | Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer | Completed | No Results Available | Ovarian Cancer | Drug: S-8184 Paclitaxel Injectable Emulsion | Determine the objective and partial response rates|Time to progression, duration of response and duration of survival | Achieve Life Sciences | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 52 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | SON-8184-1061 | March 2002 | September 2007 | September 2007 | April 24, 2002 | June 4, 2009 | https://ClinicalTrials.gov/show/NCT00034151 | ||||
| 87 | 87 | NCT03318900 | T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer | Active, not recruiting | No Results Available | COL6A3 Positive|HLA-A*0201 Positive Cells Present|PRAME Positive|Recurrent Ovarian Carcinoma | Biological: Aldesleukin|Drug: CD8-Positive T-Lymphocyte|Drug: Cyclophosphamide|Procedure: Leukapheresis|Biological: Utomilumab | Dose Limiting Toxicity Summary associated with Utomilumab Dose Escalation|Duration of in vivo persistence|Maximum Tolerated Dose (MTD) of T Cells|Maximum Tolerated Dose (MTD) of T cells + Utomilumab|Best overall response rate (BORR)|Progression free survival (PFS) | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Female | 18 Years to 75 Years (Adult, Older Adult) | Phase 1 | 18 | Other|NIH | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 2016-0400|NCI-2018-01034|P30CA016672 | July 16, 2018 | October 31, 2021 | October 31, 2021 | October 24, 2017 | October 25, 2021 | M D Anderson Cancer Center, Houston, Texas, United States | https://ClinicalTrials.gov/show/NCT03318900 | |||
| 88 | 88 | NCT01832116 | 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients | MMOT | Completed | No Results Available | Ovarian Neoplasms|Ovarian Diseases|Adnexal Diseases|Pancreatic Neoplasms|Digestive System Neoplasms|Digestive System Diseases|Pancreatic Diseases | Drug: 89Zr-MMOT0530A | The in vivo biodistribution measured in SUV values and organ pharmacokinetics (PK) of 89Zr-MMOT0530A|The 89Zr-MMOT0530A tumor uptake measured in SUV related to the response to DMOT4039A therapy according to RECISt 1.1 criteria|Number of patients with adverse events after 89Zr-MMOT0530A injection as a measure of safety and tolerability | University Medical Center Groningen|VU University Medical Center|Genentech, Inc. | All | 18 Years and older (Adult, Older Adult) | Phase 1 | 11 | Other|Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic | MMOT imaging | March 2013 | May 2014 | May 2014 | April 15, 2013 | October 28, 2014 | VU Medical Center, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands | https://ClinicalTrials.gov/show/NCT01832116 | ||
| 89 | 89 | NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | Recruiting | No Results Available | Advanced Solid Tumor|Platinum-Resistant Ovarian Cancer|Platinum-Resistant Urothelial Carcinoma|High-grade Glioma | Drug: NTX-301|Drug: Platinum-based Chemotherapy|Drug: Temozolomide | Safety & Tolerability: Incidence, type, and severity of Adverse Events (AE)|Safety & Tolerability: Dose-limiting Toxicities (DLT)|Incidence of DLTs according to the MTD/RP2D evaluation process|Pharmacokinetics (PK): Maximum observed concentration (Cmax)|Pharmacokinetics (PK): Time to Cmax (Tmax)|Pharmacokinetics (PK): Trough concentrations|Pharmacokinetics (PK): Area under the concentration-time curve (AUC0-t)|Pharmacokinetics (PK): Apparent terminal elimination half-life (t1/2) | Xennials Therapeutics Australia Pty Ltd|Pinotbio, Inc. | All | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 125 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | XNTR-20-02 | August 25, 2021 | August 2023 | November 2023 | April 20, 2021 | January 28, 2022 | St. Vincent's Hospital - The Kinghorn Cancer Center, Darlinghurst, New South Wales, Australia|St. George Private Hospital, Kogarah, New South Wales, Australia|Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia | https://ClinicalTrials.gov/show/NCT04851834 | |||
| 90 | 90 | NCT03113487 | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Recruiting | No Results Available | Recurrent Platinum-Resistant Fallopian Tube Carcinoma|Recurrent Platinum-Resistant Ovarian Carcinoma|Recurrent Platinum-Resistant Primary Peritoneal Carcinoma | Biological: Modified Vaccinia Virus Ankara Vaccine Expressing p53|Biological: Pembrolizumab | Response rate (complete response [CR] + partial response [PR])|Progression free survival (PFS)|Median overall survival|Clinical benefit (CR+PR+ stable disease [SD] > 6 months)|Incidence of adverse events|Biomarker analysis | City of Hope Medical Center|National Cancer Institute (NCI) | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 28 | Other|NIH | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 16448|NCI-2017-00555|P30CA033572 | February 1, 2018 | January 6, 2022 | January 6, 2022 | April 13, 2017 | February 11, 2021 | City of Hope Medical Center, Duarte, California, United States | https://ClinicalTrials.gov/show/NCT03113487 | |||
| 91 | 91 | NCT01460979 | Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma | Completed | No Results Available | Genital Diseases, Female|Ovarian Diseases|Ovarian Neoplasms|Endometrial Neoplasms | Drug: Temsirolimus | progression-free survival|rate and duration of stable diseases according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and Gynecologic Cancer Intergroup (GCIG)-criteria for ovarian cancer|progression-free survival according to RECIST 1.1 and cancer antigen 125 (CA 125) (for ovarian cancer) (biological progression-free survival (PFSbio))|overall survival|safety and toxicity, i.e. type, frequency, severity and duration of adverse reactions|quality of life according to European Organisation for Research and Treatment of Cancer (EORTC) questionaires "QLQ C30", "QLQ OV28" and "QLQ-EN24"|rate and duration of stable diseases according to RECIST-criteria for endometrial cancer | AGO Study Group | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 47 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | AGO-GYN 8 | October 2011 | June 2015 | November 2015 | October 27, 2011 | February 29, 2016 | Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany|Universität Erlangen-Nürnberg, Erlangen, Bayern, Germany|Klinikum rechts der Isar der Technischen Universität, München, Bayern, Germany|Klinikum der J. W. Goethe-Universität, Frankfurt am Main, Hessen, Germany|Universitätsklinikum Gießen-Marburg, Standort Marburg, Marburg, Hessen, Germany|Klinikum Offenbach, Offenbach, Hessen, Germany|Universitätsklinikum Greifswald der Ernst-Moritz-Arndt-Universität, Greifswald, Mecklenburg Vorpommern, Germany|Klinikum Göttingen, Georg-August-Universität, Göttingen, Niedersachsen, Germany|Gynäkologisch-onkologische Praxis, Hannover, Niedersachsen, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany|Kliniken Essen Mitte, Evang. Huyssens Stiftung/Knappschaft GmbH, Essen, Nordrhein-Westfalen, Germany|Städt. Klinikum Solingen gGmbH, Solingen, Nordrhein-Westfalen, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein, Germany|Charité, Campus Virchow Klinikum, Berlin, Germany|GYNAEKOLOGICUM Bremen, Bremen, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany | https://ClinicalTrials.gov/show/NCT01460979 | |||
| 92 | 92 | NCT04840589 | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors | Recruiting | No Results Available | Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Platinum-Resistant Ovarian Carcinoma|Refractory Ovarian Carcinoma | Drug: BET Bromodomain Inhibitor ZEN-3694|Biological: Ipilimumab|Biological: Nivolumab | Safety and tolerability|Phase 2 recommended dose for the combined regimens|Objective response rate (ORR)|Progression-free survival|Overall survival|Incidence of adverse events|Clinical benefit | National Cancer Institute (NCI) | All | 18 Years and older (Adult, Older Adult) | Phase 1 | 36 | NIH | Interventional | Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | NCI-2021-02850|10433|UM1CA186690 | October 6, 2021 | January 1, 2023 | January 1, 2023 | April 12, 2021 | January 31, 2022 | Case Western Reserve University, Cleveland, Ohio, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States | https://ClinicalTrials.gov/show/NCT04840589 | |||
| 93 | 93 | NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | Terminated | No Results Available | Solid Tumors|Advanced Triple Negative Breast Cancer|Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer|Advanced Metastatic Castration-Resistant Prostate Cancer|Advanced Platinum-Resistant Ovarian Cancer | Drug: TRX518|Drug: Cyclophosphamide|Drug: Avelumab | Phase 1b: Number of subjects with dose limiting toxicities which will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0)|Phase 1b: Identify the recommended Phase 2 dose (RP2D) of CTX in combination with fixed doses of TRX518 ± avelumab|Phase 2a: Efficacy in Breast and Ovarian Cancer Groups: objective response rate|Phase 2a: Efficacy in Prostate Cancer Group: objective response rate|To determine the objective disease control rate (ODCR) according to modified RECIST 1.1 in breast and ovarian cancer groups|To determine the objective disease control rate (ODCR) according to modified RECIST 1.1 and PCWG3 guidelines in prostate cancer group|To determine the duration of response according to modified RECIST 1.1 in breast and ovarian cancer groups|To determine the duration of response according to modified RECIST 1.1 and PCWG criteria in prostate cancer group|To determine the progression free survival according to RECIST 1.1 in breast and ovarian cancer groups|To determine the progression free survival according to RECIST 1.1 and PCWG3 criteria in prostate cancer group|To determine overall survival (OS) in all cancer groups|To determine the PSA response in prostate cancer group|Evaluate the effect of TRX518 in combination with cyclophosphamide and avelumab on lymphoid cell subset numbers and function|Time to peak concentration (Tmax)|TRX518 and avelumab peak concentration (Cmax)|Area under the curve (AUC)|Assess TRX518 and avelumab immunogenicity | Leap Therapeutics, Inc.|Pfizer|Merck KGaA, Darmstadt, Germany | All | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 10 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | TRX518-004 | May 20, 2019 | July 14, 2020 | July 14, 2020 | March 4, 2019 | October 27, 2020 | Horizon Oncology Research, Lafayette, Indiana, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Virginia, Charlottesville, Virginia, United States | https://ClinicalTrials.gov/show/NCT03861403 | |||
| 94 | 94 | NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | Recruiting | No Results Available | Renal Cell Carcinoma (RCC)|Urothelial Carcinoma|Primary Peritoneal Cancer|Platinum-resistant Ovarian Cancer (PROC)|Serous Epithelial Ovarian Cancer|Fallopian Tube Cancer | Drug: DSP-7888 Dosing Emulsion|Drug: Nivolumab|Drug: Pembrolizumab | Phase Ib: Determination of the safety and tolerability of DSP-7888 Dosing Emulsion given intradermally with a checkpoint inhibitor (Nivolumab or Pembrolizumab) in adult patients with advanced solid tumors by assessing dose-limiting toxicities (DLTs).|Phase Ib: Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs).|Phase II: Evaluation of the preliminary antitumor activity of DSP-7888 Dosing Emulsion administered with pembrolizumab in terms of Objective Response Rate (ORR) in patients with platinum-resistant ovarian cancer (PROC).|Phase Ib: Objective response rate (ORR)|Phase Ib: Disease control rate (DCR)|Phase Ib: Duration of response (DOR)|Phase Ib: Progression-free survival (PFS)|Phase Ib: 6-month PFS|Phase Ib: Overall survival (OS)|Phase II: DOR|Phase II: DCR|Phase II: PFS|Phase II: 6-month PFS|Phase II: OS|Phase II: Immune objective response rate (iORR)|Phase II: Immune disease control rate (iDCR)|Phase II: Immune progression-free survival (iPFS)|Phase II: immune DOR (iDOR)|Phase II: Evaluation of the safety and tolerability of DSP-7888 Dosing Emulsion administered with pembrolizumab. | Sumitomo Dainippon Pharma Oncology, Inc | All | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 84 | Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | BBI-DSP7888-102CI | December 14, 2017 | August 2023 | February 2024 | October 17, 2017 | September 10, 2021 | Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UC San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Miami Cancer Institute at Baptist Health, Miami, Florida, United States|AdventHealth Cancer Institute, Orlando, Florida, United States|University Cancer and Blood Center, Athens, Georgia, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Horizon Oncology Research, Lafayette, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|UC Health, LLC, Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|West Cancer Clinic, Germantown, Tennessee, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Summit Cancer Centers, Spokane, Washington, United States|Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada|SMBD Jewish General Hospital, Montréal, Quebec, Canada | https://ClinicalTrials.gov/show/NCT03311334 | |||
| 95 | 95 | NCT00343044 | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | Completed | Has Results | Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer | Drug: Topotecan|Drug: Bevacizumab | Progression Free Survival|Evaluation of Overall Survival|Objective Response Rate|Number or Participants With Toxicity | Benaroya Research Institute|GlaxoSmithKline|Genentech, Inc. | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 40 | Other|Industry | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 3040200|AVF3648s | June 2006 | January 2010 | August 2011 | June 22, 2006 | May 15, 2015 | May 15, 2015 | Virginia Mason Medical Center, Seattle, Washington, United States|Puget Sound Oncology Consortium (PSOC), Seattle, Washington, United States | https://ClinicalTrials.gov/show/NCT00343044 | ||
| 96 | 96 | NCT04739800 | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | Recruiting | No Results Available | Fallopian Tube Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Platinum-Refractory Fallopian Tube Carcinoma|Platinum-Refractory Ovarian Carcinoma|Platinum-Refractory Primary Peritoneal Carcinoma|Recurrent Fallopian Tube Clear Cell Adenocarcinoma|Recurrent Fallopian Tube Endometrioid Adenocarcinoma|Recurrent Fallopian Tube Mucinous Adenocarcinoma|Recurrent Fallopian Tube Transitional Cell Carcinoma|Recurrent Fallopian Tube Undifferentiated Carcinoma|Recurrent High Grade Fallopian Tube Serous Adenocarcinoma|Recurrent High Grade Ovarian Serous Adenocarcinoma|Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma|Recurrent Low Grade Ovarian Serous Adenocarcinoma|Recurrent Ovarian Clear Cell Adenocarcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Ovarian Mucinous Adenocarcinoma|Recurrent Ovarian Seromucinous Carcinoma|Recurrent Ovarian Transitional Cell Carcinoma|Recurrent Ovarian Undifferentiated Carcinoma|Recurrent Platinum-Resistant Fallopian Tube Carcinoma|Recurrent Platinum-Resistant Ovarian Carcinoma|Recurrent Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Clear Cell Adenocarcinoma|Recurrent Primary Peritoneal Endometrioid Adenocarcinoma|Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma|Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma|Recurrent Primary Peritoneal Transitional Cell Carcinoma|Recurrent Primary Peritoneal Undifferentiated Carcinoma|Refractory Fallopian Tube Clear Cell Adenocarcinoma|Refractory Fallopian Tube Endometrioid Adenocarcinoma|Refractory Fallopian Tube Mucinous Adenocarcinoma|Refractory Fallopian Tube Transitional Cell Carcinoma|Refractory Fallopian Tube Undifferentiated Carcinoma|Refractory High Grade Fallopian Tube Serous Adenocarcinoma|Refractory High Grade Ovarian Serous Adenocarcinoma|Refractory Low Grade Fallopian Tube Serous Adenocarcinoma|Refractory Low Grade Ovarian Serous Adenocarcinoma|Refractory Ovarian Clear Cell Adenocarcinoma|Refractory Ovarian Endometrioid Adenocarcinoma|Refractory Ovarian Mucinous Adenocarcinoma|Refractory Ovarian Seromucinous Carcinoma|Refractory Ovarian Transitional Cell Carcinoma|Refractory Ovarian Undifferentiated Carcinoma|Refractory Primary Peritoneal Clear Cell Adenocarcinoma|Refractory Primary Peritoneal Endometrioid Adenocarcinoma|Refractory Primary Peritoneal High Grade Serous Adenocarcinoma|Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma|Refractory Primary Peritoneal Transitional Cell Carcinoma|Refractory Primary Peritoneal Undifferentiated Carcinoma | Drug: Cediranib Maleate|Biological: Durvalumab|Drug: Olaparib|Drug: Paclitaxel|Drug: Pegylated Liposomal Doxorubicin Hydrochloride|Drug: Topotecan Hydrochloride | Progression free survival|Objective response rate|Duration of response|Overall survival|Incidence of adverse events | National Cancer Institute (NCI)|NRG Oncology | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 164 | NIH|Other | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | NCI-2021-00615|NRG-GY023|U10CA180868 | April 28, 2021 | April 30, 2022 | April 30, 2022 | February 5, 2021 | January 31, 2022 | Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|Cancer Center at Saint Joseph's, Phoenix, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|John Muir Medical Center-Concord Campus, Concord, California, United States|Sutter Davis Hospital, Davis, California, United States|Palo Alto Medical Foundation-Fremont, Fremont, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Memorial Medical Center, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Pacific Central Coast Health Center-San Luis Obispo, San Luis Obispo, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Mission Hope Medical Oncology - Santa Maria, Santa Maria, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|John Muir Medical Center-Walnut Creek, Walnut Creek, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Rocky Mountain Cancer Centers - Centennial, Centennial, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|CTCA at Southeastern Regional Medical Center, Newnan, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Saint Anthony's Health, Alton, Illinois, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Illinois CancerCare-Dixon, Dixon, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Sudarshan K Sharma MD Limited-Gynecologic Oncology, Hinsdale, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Illinois CancerCare - Washington, Washington, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|UofL Health Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Minnesota Oncology - Burnsville, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Parkland Health Center - Farmington, Farmington, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Cancer Partners of Nebraska - Pine Lake, Lincoln, Nebraska, United States|Southeast Nebraska Cancer Center - 68th Street Place, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States|Dickstein Cancer Treatment Center, White Plains, New York, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Summa Health System - Akron Campus, Akron, Ohio, United States|Aultman Alliance Community Hospital, Alliance, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio, United States|Mount Carmel Grove City Hospital, Grove City, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Saint Rita's Medical Center, Lima, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Mercy Health Perrysburg Cancer Center, Perrysburg, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|Mercy Health - Saint Anne Hospital, Toledo, Ohio, United States|University Hospitals Sharon Health Center, Wadsworth, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|Bristol Regional Medical Center, Bristol, Tennessee, United States|Regional Cancer Center at Indian Path Community Hospital, Kingsport, Tennessee, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Thompson Cancer Survival Center - West, Knoxville, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Methodist Willowbrook Hospital, Houston, Texas, United States|Houston Methodist West Hospital, Houston, Texas, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States|Houston Methodist The Woodlands Hospital, The Woodlands, Texas, United States|Wellmont Medical Associates-Bristol, Bristol, Virginia, United States|Southwest VA Regional Cancer Center, Norton, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Jefferson Healthcare, Port Townsend, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|West Virginia University Charleston Division, Charleston, West Virginia, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Cancer Center-Metro Medical Center Bayamon, Bayamon, Puerto Rico|HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico|Doctors Cancer Center, Manati, Puerto Rico|Instituto Oncologia Moderna Ponce, Ponce, Puerto Rico|San Juan Community Oncology Group, San Juan, Puerto Rico|Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico|San Juan City Hospital, San Juan, Puerto Rico | https://ClinicalTrials.gov/show/NCT04739800 | |||
| 97 | 97 | NCT05026606 | Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Recruiting | No Results Available | Recurrent Fallopian Tube Clear Cell Adenocarcinoma|Recurrent Ovarian Clear Cell Adenocarcinoma|Recurrent Platinum-Resistant Fallopian Tube Carcinoma|Recurrent Platinum-Resistant Ovarian Carcinoma|Recurrent Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Clear Cell Adenocarcinoma | Biological: Etigilimab|Biological: Nivolumab | Objective response rate (ORR)|Incidence of adverse events|Median immune-related progression free survival (irPFS)|Disease control rate (DCR)|Molecular changes|Immunological changes | M.D. Anderson Cancer Center | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 20 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 2021-0511|NCI-2021-08531 | October 1, 2021 | May 31, 2023 | May 31, 2023 | August 30, 2021 | November 24, 2021 | M D Anderson Cancer Center, Houston, Texas, United States | https://ClinicalTrials.gov/show/NCT05026606 | |||
| 98 | 98 | NCT04019288 | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | No Results Available | Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Fallopian Tube Carcinoma|Refractory Ovarian Carcinoma|Refractory Primary Peritoneal Carcinoma | Drug: Batiraxcept|Biological: Durvalumab | Incidence of adverse events | M.D. Anderson Cancer Center|Aravive Biologics Inc|AstraZeneca | Female | 18 Years and older (Adult, Older Adult) | Phase 1|Phase 2 | 19 | Other|Industry | Interventional | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | 2019-0149|NCI-2019-02580 | October 11, 2019 | September 30, 2022 | September 30, 2022 | July 15, 2019 | December 23, 2021 | M D Anderson Cancer Center, Houston, Texas, United States | https://ClinicalTrials.gov/show/NCT04019288 | |||
| 99 | 99 | NCT02835833 | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | Completed | No Results Available | Renal Cell Carcinoma|Colorectal Adenocarcinoma|Non-squamous Non-small Cell Lung Cancer|Platinum-refractory Ovarian Carcinoma|Cervical Carcinoma | Drug: Nintedanib|Drug: Bevacizumab | Number of participants with adverse events as a measure of safety and tolerability|Maximum tolerable dose of Nintedanib|Objective tumor response rate|Progression-free survival|Plasma level of vascular endothelial growth factor (VEGF)|Plasma level of platelet-derived growth factor (PDGF)|Plasma level of vascular endothelial growth factor and receptor (VEGF-R)|Plasma level of phosphatidylinositol-glycan biosynthesis class F protein (PIGF)|Plasma level of fibroblast growth factor (FGF) | University of Alabama at Birmingham|Boehringer Ingelheim | All | 19 Years and older (Adult, Older Adult) | Phase 1 | 21 | Other|Industry | Interventional | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | F160202011 (UAB 15108) | June 9, 2016 | April 14, 2018 | June 14, 2018 | July 18, 2016 | July 10, 2018 | University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States | https://ClinicalTrials.gov/show/NCT02835833 | |||
| 100 | 100 | NCT04753216 | Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Not yet recruiting | No Results Available | Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Fallopian Tube Carcinoma|Refractory Ovarian Carcinoma|Refractory Primary Peritoneal Carcinoma | Biological: Bevacizumab|Drug: Irinotecan Sucrosofate | Objective response rate (ORR)|Overall best response|Clinical benefit rate (CBR)|Duration of response (DOR)|Duration of stable disease|Time to response (TTR)|Median progression-Free Survival (PFS)|Progression free survival|Incidence of adverse events | Northwestern University|Ipsen Biopharmaceuticals | Female | 18 Years and older (Adult, Older Adult) | Phase 2 | 30 | Other | Interventional | Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | NU 20G02|STU00213582|P30CA060553|NCI-2021-00765 | March 15, 2021 | July 1, 2023 | July 1, 2024 | February 15, 2021 | February 15, 2021 | Northwestern University, Chicago, Illinois, United States | https://ClinicalTrials.gov/show/NCT04753216 |